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Ankur Garg 
REITERATIVE FGF SIGNALING DETERMINES THE IDENTITY AND 
MORPHOLOGY OF THE LACRIMAL GLAND 
The lacrimal gland plays an essential role in protection of the ocular surface by secreting 
the aqueous component of the tear film. Deficiency in the lacrimal gland is the main 
cause of dry eye disease, but existing treatments only alleviate the symptoms without 
curing the underlying disease. To develop curative measures, a thorough understanding 
of lacrimal gland development is needed. Lacrimal gland is formed as a result of 
interaction between the neural crest-derived mesenchyme and the conjunctival 
epithelium. The mesenchyme secretes the chemo-attractive signal of Fgf10, which binds 
to epithelial Fgfr2b and co-receptor heparan sulphate proteoglycans, to promote budding 
and branching morphogenesis of the lacrimal gland. However, the mechanism by which 
Fgf10 expression is regulated within the neural crest and the direct downstream targets of 
Fgf signaling in the epithelium are currently unknown. In this study, we show that FGF 
signaling mediated by protein phosphatase Shp2 is required for the proper patterning and 
differentiation of the neural crest-derived mesenchyme to produce Fgf10.  Genetic 
evidence further demonstrates that Shp2 is recruited by Frs2α to activate Ras-MAPK 
signaling downstream to Fgfr1 and Fgfr2 but not to Pdgfrα in the neural crest. By 
differential gene expression analysis, we identified homeodomain transcription factor 
Alx4 as the key effector of Shp2 signaling to control expression of Fgf10 in the 
periocular mesenchyme. Loss of function ALX4/Alx4 mutation disrupted lacrimal gland 
development in both human and mouse. Our results reveal a FGF-Shp2-Alx4-Fgf10 axis 
in regulating neural crests during lacrimal gland development. In addition, we also show 
that Fgf signaling cascade mediated by Pea3 family of transcription factors are critical for 
lacrimal gland duct elongation and branching. High-throughput gene expression analysis 
revealed that Pea3 genes were important for establishing the tissue identity of the 
lacrimal gland.  Loss of Pea3 resulted in upregulation of Notch signaling with the 
concomitant loss in the expression of the members of Six family of transcription factors 
and a switch of cell fate to the epidermal skin-like cells. These findings show that Fgf 
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signaling is used reiteratively to establish the identity of both the epithelium and 
mesenchyme of the lacrimal gland.   
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1 Introduction 
1.1 Lacrimal gland development in human and mouse 
1.1.1 Tear film and role of lacrimal gland 
The lacrimal gland is a tubulo-acinar exocrine gland which produces the aqueous 
component of the tear, including water, electrolytes and proteins [1]. Critical for the 
ocular health and quality vision, the tear forms a smooth refractive film over the cornea, 
lubricating the cornea and conjunctiva, supporting the ocular surface metabolism, 
flushing away dirt and noxious stimuli. The tear film is composed of three layers- 1) the 
outermost lipid layer secreted by Meibomian glands prevents evaporation of tears, 2) the 
middle aqueous layer produced by the lacrimal gland and the accessory glands of Krause 
and Wolfring accounts for over 90% of the tear volume, and 3) the innermost mucous 
layer produced by the cornea and conjunctiva anchors the tear film to the ocular surface 
[2]. By releasing immunoglobulins into the tear, the lacrimal gland also functions as the 
secretary immune system of the eye to protect the ocular surface against infection arising 
from constant environmental exposure [3].   
 
1.1.2 Structure of Lacrimal gland 
In humans, the secretory component of the lacrimal system is the lacrimal gland located 
within the bony upper orbit of the eye, emptying its secretions into an anastomosed duct 
system that delivers the fluid to the ocular surface. The excretory part of the lacrimal 
system lies at the nasal side of the eye, draining the excessive fluid through the tear duct 
connected to the lacrimal sac and nasal passages (Fig. 1) [4].  In rodents, however, the 
lacrimal gland is comprised of two lobular structures: the intra-orbital and the ex-orbital. 
The primary lacrimal gland is the ex-orbital lobe, located just beneath the ear and 
connected to the eye via a long duct that joins the intra-orbital lobe just prior to reaching 
the eye (Fig. 2) [5]. The lacrimal gland epithelium is composed of three major cell types: 
acinar, duct and myoepithelial cells. The primary secretory apparatus are acinar cells 
which make up to 80% of the gland. The luminal side of the acinar cells are connected to 
the ducts lined by cuboidal duct cells, which constitute 10-12% of the lacrimal gland cell 
population and contribute to 30% of the lacrimal gland fluid secretions [6]. Myoepithelial 
cells are the third major component of the lacrimal gland, surrounding the basal side of 
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both acinar and ductal cells.  Their function is to squeeze the secretory cells to expel the 
fluid into the duct [5]. Besides these three main cell types, the lacrimal gland stroma also 
contains fibroblast cells which produce collagens and mast cells secreting histamines and 
other matrix proteins in the interstitial spaces [4]. The vasculature of the lacrimal gland 
also brings in plasma cells, lymphocytes, dendritic cells and macrophages, which provide 
immune protection to the ocular surface [5, 7].  The function of the lacrimal system is 
controlled by sensory afferent nerves from the cornea and conjunctiva and motor efferent 
parasympathetic and sympathetic nerves innervating the lacrimal gland.  Together, they 
ensures the optimum volume and quality of tear secretion in response to environmental 
stress [5]. 
 
1.1.3 Dry eye disease 
Dry eye disease affects more than 3.2 million middle-aged or older women and 1 million 
males aged 50 or more within the United States and the prevalence is increasing rapidly 
[8, 9]. Dry eye occurs when the quality and amount of tears is not sufficient to maintain 
the ocular surface homeostasis and the risks of this incidence occurring increase with age. 
There are two forms of dry eye- 1) Evaporative: caused by deficiency in the lipid layer 
which is often due to the blockage of the Meibomian gland located in the eyelid. Poor 
quality or insufficient oil layer can result in faster vaporization of the tears 2) Aqueous-
deficient: occurs due to deficiency in the lacrimal gland functional unit responsible for 
secreting the aqueous layer, the major component of the tear film. These clinical 
manifestations of these two etiologies could occur separately or in combination. 
 
1.1.3.1 Current and proposed treatment strategies 
Common forms of treatment include over-the-counter topical medications such as 
artificial tears, gels and ointments, prescription-based anti-inflammatory drugs such as 
cyclosporine and lifitegrast, recommendations for changing lifestyle and environment, 
devices which help stimulate tear production as well as surgical intervention to plug the 
tear drainage system. However, these treatments address the symptoms but do not tackle 
the underlying glandular deficiencies and hence, do not provide a permanent cure. To 
improve the treatment strategy for dry eye, several lines of research have been taking 
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place with the overarching goal of better understanding of the underlying cause of the 
disease which will help develop better treatments. One line of research is to study the 
mechanisms of development and function of Meibomian gland with the goal of 
understanding its anatomy and physiology, lipid composition of tears and ways by which 
lipid production can be stimulated and stabilized. Since the aqueous layer is the principal 
component of the tears, lack of which causes dryness in the eye, many laboratories are 
searching the ways to treat the lacrimal gland-associated deficiencies. In this direction, 
one area of research is development of topical nerve stimulators in cases of deficiency in 
the corneal nerves and their excitatory capacity and another line of focus is to understand 
the lacrimal gland development and ways by which it can be rebuilt via patient’s own 
stem cells. Scientists in the latter field have proposed two strategies, one is to promote 
intrinsic regeneration by identifying the factors which can stimulate this process or 
develop artificial lacrimal gland implants. There have been significant advancements in 
this area which have pushed forward the task of rebuilding lacrimal gland and brought it 
closer to reality, however, clinical transition still remains elusive.  
 
1.1.3.2 Why study lacrimal gland development? 
Impairment of the lacrimal gland can result in the debilitating condition known as the 
aqueous-deficient dry eye disease, which may progress to corneal abrasion and vision 
loss. The most significant risk factor for the dry eye disease is aging, causing structural 
and functional changes in the lacrimal gland characterized by atrophied acini, duct 
obstruction, increasing lymphocytic infiltration and decrease in stimulated protein 
secretion [10]. Lacrimal gland dysfunction can also arise from inflammation triggered by 
the dry environment, auto-immune attack on exocrine glands as in Sjӧgren’s syndrome 
and rheumatoid arthritis, side effects of chemo and radiation therapies and congenital 
defects [11-13]. However, all the current clinical interventions are palliative, not curing 
the underlying lacrimal gland deficiency. To this end, regeneration of the damaged 
lacrimal gland or replacement by bioengineered implants can potentially provide 
permanent cures for the dry eye disease. This would require a thorough understanding of 
the molecular mechanism of lacrimal gland development and regeneration.  
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1.1.4 The molecular mechanism of lacrimal gland development  
1.1.4.1 Signaling interactions: the epithelium - mesenchyme interaction  
Lacrimal gland forms as a result of interactions between the conjunctival epithelium and 
the periocular mesenchyme. In human, it begins as a thickening of the epithelium at the 
superior conjunctival fornix, which subsequently invades the underlying mesenchyme to 
form a highly branched gland [14]. This is recapitulated in mouse as the budding of the 
conjunctival epithelium at the temporal side of the eye at the E13.5 stage (Fig. 2) [15]. 
This tubular bud elongates posteriorly toward the ear, accompanied by condensation of 
the surrounding mesenchyme [16].  This process apparently can occur independently of 
retina and lens development, as the lacrimal gland bud develops even in mouse mutants 
lacking the eyeball [17].  Starting at E15.5, the lacrimal gland bud branches out to form a 
complex intra-orbital and ex-orbital multi-lobular structure, eventually composed of a 
system of acini, ducts, myoepithelial cells, nerves, plasma cells and connective tissue.  
 
1.1.4.2 Role of FGF10 signaling 
The inductive signals to initiate lacrimal gland budding and branching morphogenesis are 
Fibroblast growth factors (FGFs). Fgf10 is expressed in a distinctive domain in the 
mesenchyme surrounding the epithelial bud and its expression persists throughout 
lacrimal gland development.  By contrast, Fgf7 expression in the mesenchyme is more 
diffusive [15, 18]. 
 
Both recombinant human FGF10 and FGF7 were able to induce ectopic budding of the 
lacrimal gland epithelium in explant culture of embryonic eye [15]. Remarkably, ectopic 
glands can even be induced in the cornea by transgenic expression of rat Fgf10 or human 
FGF7 in the lens, but not by other FGFs, underlying the potency and specificity of the 
FGF7 subfamily of FGFs for ocular gland development [18, 19]. Fgf10 null mice exhibit 
a complete loss of the epithelial component of the lacrimal gland despite an intact 
mesenchyme, while Fgf7 knockout mice have normal lacrimal glands, indicating that 
Fgf10 is the primary driver of lacrimal gland development [15, 18, 19]. 
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Figure 1. Schematic of Lacrimal gland functional unit. The lacrimal gland functional 
unit is comprised of (a) the lacrimal gland, (b) Sensory afferent nerves from the cornea 
and conjunctiva, (c) motor efferent nerves originating from the central nervous system 
which innervate lacrimal gland, (d) the excretory tear duct for drainage of the excess 
fluid. Impairment in any components of lacrimal gland function unit can destabilize the 
tear film and cause the dry eye disease. 
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In fact, Fgf10 is haploinsufficient for the lacrimal gland development in mouse, whereas 
heterozygous FGF10 mutations in humans can lead to aplasia of lacrimal gland and 
salivary gland (ALSG), a rare disorder characterized by dryness in the eye and mouth 
(OMIM #180920) [20]. A more severe congenital disorder called Lacrimo-auriculo-
dento-digital (LADD) syndrome affecting lacrimal and salivary glands, ears, teeth and 
distal limbs has been associated with missense mutations in FGF10 (OMIM #149730) 
[21]. The majority of FGF10 mutations in LADD patients disrupt protein stability or 
receptor interaction, but missense mutation affecting secretion and nuclear localization of 
FGF10 has also been identified [22, 23]. The LADD mutations are thought to have 
dominant-negative instead of simple loss-of-function effect, which may explain why 
more organs are affected in LADD syndrome than ALSG syndrome [21].  These 
observations highlight the pivotal role of FGF10 /Fgf10 in multi-organ development, but 
also raise the interesting question why lacrimal gland development is particularly 
sensitive to the FGF10/Fgf10 dosage. 
 
In addition to the precise control of Fgf10 at the gene dosage level, the concentration of 
Fgf10 protein in the periocular mesenchyme is also under exquisite regulation by 
proteoglycans within the extracellular matrix (ECM) (Fig. 3) [24]. Previous work from 
our lab have shown that glycosaminoglycans (GAGs) attached to proteoglycans in the 
periocular mesenchyme restricts diffusion of Fgf10 during lacrimal gland development 
[25]. Mesenchyme-specific knockouts of proteoglycan biosynthetic enzymes Ugdh 
(UDP-Glucose 6-Dehydrogenase) cause excessive diffusion of Fgf10 and disrupt lacrimal 
gland budding. Interestingly, the lacrimal gland defect can be reproduced by 
mesenchymal deletion of heparan sulfate (proteoglycan) modification enzymes Ndst1/2 
(N-deacetylase/N-sulfotransferase), but not by 2-O-sulfotransferases (Hs2st) and 6-O-
sulfotransferases (Hs6st1/2), suggesting that N-sulfation of heparan sulfates is essential 
for regulating Fgf10 dissemination [25].   
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Figure 2. Lacrimal gland development in mouse. Transverse sections of mouse 
embryos at different stages are shown. Lacrimal gland development begins with 
thickening of the CE at E13.5 induced by Fgf10 from the surrounding mesenchyme. 
These epithelial cells further grow and elongate into a bud from E14.5 through E15.5. 
Branching of LG initiates at E16.5 under the additional influence of BMP7 signaling, 
eventually forming a multi-lobular tubulo-acinar structure at E19.5. Lacrimal gland 
continues to develop even during postnatal stages to become a mature gland capable of 
regulated tear secretion in adults. L, lens; R, Retina; CE, conjunctival epithelium; LG, 
lacrimal gland. 
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Consistent with this, mutating the key residues of FGF10 that interact with heparan 
sulfates also resulted in increased diffusion range of FGF10 in the ECM [26]. The 
resulting mutant FGF10 was found to behave like FGF7, which has lower affinity to 
heparan sulfates and preferentially promotes lacrimal gland branching instead of 
elongation.  On the other hand, FGF signaling has been shown to cooperate with 
transcription factor Barx2 in the lacrimal gland epithelium to regulate the expression of 
ECM remodeling enzymes matrix metalloproteinases (MMP2 and MMP9), which are 
secreted into the mesenchyme to promote the release of Fgf10 from proteoglycans [27]. 
This presents a positive feedback mechanism to modulate the Fgf10 concentration ahead 
of the invading epithelial bud. One question that remains unresolved is whether the 
control of Fgf10 diffusion by proteoglycans generate a chemoattractive gradient to guide 
lacrimal gland development. This is partly due to the lack of a sensitive assay to 
determine the endogenous concentration of Fgf10 in the periocular mesenchyme.  In this 
regard, it is worth noting that although endogenous Fgf10 is also expressed in a localized 
fashion in the embryonic lung, a recent study showed that it can be functionally 
substituted by ubiquitous expression of Fgf10 during branching morphogenesis [28]. This 
raises the possibility that Fgf10 gradient may even be dispensable for budding and 
branching of glandular organs.  
 
The cognate receptor for Fgf10 is Fgf receptor 2(III)b (Fgfr2b) expressed in the lacrimal 
gland epithelium.  Both epithelial ablation of Fgfr2 in vivo and knock down of Fgfr2b ex 
vivo disrupts lacrimal gland development [15, 29].  Consistent with this, FGFR2 
mutations have been identified in LADD patients [21]. Nevertheless, a heterozygous 
mutation in the kinase domain of FGFR3 has also been reported in a LADD family. 
Because these affected patients do not exhibit congenital abnormalities typically 
associated with syndromes caused by activating FGFR3 mutations, it was assumed that 
this LADD mutation is a loss-of-function allele.  However, Fgfr3 is known to have a very 
low affinity to Fgf10 and Fgfr3 knockout mouse has normal lacrimal gland (AG and XZ, 
unpublished results).  Therefore, functional study is needed to resolve the nature of this 
LADD-associated FGFR3 mutations. It is also interesting to note that heterozygous 
ablation of Fgfr2c, which is not the cognate receptor for Fgf10, results in secondary 
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branching defects in the lung, kidney and lacrimal gland [30]. Since Fgfr2 heterozygous 
null mouse exhibits no overt phenotype, it is believed that Fgfr2c deletion creates a gain-
of-function allele as a result of a splicing switch in Fgfr2 locus, leading to ectopic 
expression and activation of Fgfr2b in the mesenchyme. Fgfr2c mutant lacrimal gland 
retains a mesenchymal sac without Fgf10 expression.  It remains to be determined how 
aberrant Fgfr2b signaling can be activated without Fgf10 in the mesenchyme. 
 
The assembly of FGF signaling complex on the cell surface also requires heparan sulfates 
as co-receptors (Fig. 3). Interestingly, the lacrimal gland bud specifically expresses Ndst1 
enzyme in the tip cells, but not in the follower cells that form the stalk of the lacrimal 
gland bud[29]. Epithelial ablation of Ndst1 not only disrupted N-sulfation of heparan 
sulfates, but also abrogated lacrimal gland bud formation. Similarly, both 2-O and 6-O 
sulfation of heparan sulfates contribute to Fgf10-induced signaling process since the 
deletion of Hs6st and Hs2st in the lacrimal gland epithelium resulted in the stunted 
growth or no bud formation [31]. Indeed, using a FGF ligand and carbohydrate 
engagement assay (LACE), we showed that recombinant Fgf10/Fgfr2b proteins were able 
to form a tight binding complex on the lacrimal gland bud in situ, which was disrupted in 
heparan sulfate N- or O-sulfation mutants [29, 31]. On the other hand, these 
modifications of heparan sulfates are also under the control of FGF signaling, as 
epithelial ablation of Fgfr2 abolished N-sulfation of heparan sulfates [29]. This positive 
feedback mechanism is mediated by Shp2, a non-receptor tyrosine phosphatase that 
transmits FGF signaling to Ras-MAPK pathway, partly by suppressing the negative Ras 
signaling regulator Sprouty2 [32].  The key targets of this signaling cascade are likely 
transcription factors Sox9 and Sox10, which have been shown to regulate the expression 
of heparan sulfate 3-O-sulfotransferases in an FGF-signaling-dependent manner [33]. 
 
1.1.4.3 Role of BMP signaling 
While Fgf10 is expressed exclusively in the lacrimal gland mesenchyme to guide budding 
and branching of the epithelium, another growth factor Bmp7 displays a more complex 
and dynamic expression pattern during lacrimal gland development. Initially expressed in 
the periocular mesenchyme surrounding the epithelial bud, Bmp7 is later present in both 
 10
the epithelial and mesenchymal compartments of the lacrimal gland [16]. The direct 
target of Bmp7 signaling, however, appears primarily to be the lacrimal gland 
mesenchyme. Exposing isolated lacrimal gland epithelium to Bmp7 did not affect 
budding induced by Fgf10, but in the mesenchymal culture, Bmp7 resulted in increasing 
cellular proliferation and aggregation marked by expressions of connexin43, cadherins 
and α-smooth muscle actin (α-SMA) [16]. Defective condensation of the periocular 
mesenchyme was found in Bmp7 null mice, which also exhibited smaller glands with 
misplaced buds and reduced branching. It is thought that the condensation and 
proliferation of mesenchymal cells induced by BMP signaling is critical for proper 
branching morphogenesis of the lacrimal gland epithelium. In support of this model, it 
was shown that although transcription factor Foxc1 was dispensable in the lacrimal gland 
epithelium, its loss in the mesenchyme prevented BMP signaling from inducing cellular 
condensation [34]. As a result, Foxc1 null mice exhibited reduced lacrimal gland size 
with fewer terminal buds, reminiscent of Bmp7 null phenotype.  It should be noted that, 
in contrast to Bmp7, Bmp4 is found to suppress Fgf10-induced growth and elongation of 
the lacrimal gland bud in isolated epithelial culture, suggesting that BMP signaling may 
also play a direct role in the lacrimal gland epithelium [16].  BMP signaling is mediated 
by phosphorylated Smad1/5/8 proteins, which form a complex with Smad4 to activate the 
downstream transcriptional events. Indeed, a recent study showed that epithelial deletion 
of Smad4 resulted in smaller lacrimal glands with fewer branches and acini [35]. 
Interestingly, Smad4 mutant lacrimal gland accumulated pigments after birth and was 
eventually replaced by adipose tissue. These studies suggest that BMP signaling in both 
the epithelium and the mesenchyme is critical for lacrimal gland development. 
 
 1.1.4.4 Role of Wnt signaling  
Canonical Wnt signaling has been shown to interact with both FGF and BMP signaling to 
modulate lacrimal gland branching morphogenesis. Activation of the canonical Wnt 
signaling pathway prevents degradation of β-catenin in the cytoplasm, which is 
translocated into the nucleus to bind Tcf/Lef transcription factors to induce gene 
expression. Transcripts of several Wnts (both canonical and non-canonical) are present in 
the lacrimal gland during development [36]. Inhibition of Wnt signaling by knocking 
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down β-catenin using morpholinos in lacrimal gland explants led to increasing branching 
and cell proliferation and an up-regulation of Fgf10 in the mesenchyme. Activating Wnt 
signaling by Wnt3a or LiCl treatment, on the other hand, reduced proliferation of both the 
epithelial and mesenchymal components of lacrimal gland with concurrent reduction in 
the number of branches. Wnt signaling also suppressed Bmp7-induced increase of cell 
proliferation in the lacrimal gland mesenchyme. Thus, Wnt signaling regulates branching 
morphogenesis by counterbalancing the effect of Fgf10 and Bmp7 [36].  
 
1.1.4.5 Role of Notch signaling  
Maturation and homeostasis of the lacrimal gland also require Notch signaling, which is 
transmitted by nuclear translocation of the Notch Intracellular domain (NICD) that 
subsequently interacts with recombination signal binding protein for immunoglobin Jk 
region (RBP-Jk), Histone acyl transferases and Mastermind-like transcriptional co-
activator (Maml) to activate the transcription of target genes. After postnatal knockout of 
Notch1 in the ocular surface, lacrimal gland degenerates with infiltrated monocytic cells, 
resulting in marked reduction in tear volume [37]. It has also been shown that Maml-
mediated Notch signaling is responsible for maintaining the conjunctival epithelial 
identity and goblet cell differentiation. This is achieved by augmenting the expression of 
Klf4/5 transcription factors which control Muc5a expression. Indeed, lacrimal gland in 
mice with epithelial deletion of Klf5 exhibited excessive inflammation and 
disorganization of the acini [38]. More recently, Notch signaling has also been proposed 
to regulate branching morphogenesis by suppressing cleft-formation [39]. These studies 
suggest that Notch signaling contributes to both development and function of the lacrimal 
gland. 
 
 In summary, after the critical role of Fgf10 in lacrimal gland development was 
discovered less than two decades ago, it is now appreciated that FGF signaling must 
interact with other pathways, including BMP, Wnt and Notch signaling, to regulate 
lacrimal gland budding and branching morphogenesis. The recent high throughput gene 
expression analysis has further implicated IGF, TGFβ and Hippo signaling in human  
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Figure 3. Summary of signaling interactions during lacrimal gland morphogenesis.  
(Left) Fgf10 forms a heparan sulfates (HS)-dependent gradient in the periocular 
mesenchyme, inducing lacrimal gland budding by binding to both Fgfr2b and HS in the 
epithelium. This activates Shp2, which inhibits the Ras signaling repressor Spry2 and 
promotes Ras-Erk cascade to stimulate cell proliferation, survival and bud elongation. 
With transcription factors Sox9 and Barx2, FGF signaling also stimulates expressions of 
HS synthesizing enzymes (HSSE) and metalloproteinases to remodel the ECM, forming a 
positive feedback loop to enhance FGF signaling activity. (Right) Bmp7 signaling 
mediated by Foxc1 is important for mesenchymal condensation during branching 
morphogenesis. Both FGF and BMP signaling are counterbalanced by canonical Wnt 
signaling in the mesenchyme. In addition, Smad4-mediated BMP signaling and Sox9-
Sox10 cascade also directly regulates the epithelial elongation. 
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lacrimal gland, presenting a fertile research field for investigating additional pathways in 
lacrimal gland development [40]. On the other hand, our understanding of these known 
signaling in lacrimal gland remains rudimentary, lacking essential molecular details. For 
example, the lacrimal gland epithelum requires the inductive signal from the periocular 
mesenchyme, but how the mesenchyme itself is specified and whether there is reciprocal 
signals from the epithelium to the mesenchyme is not clear. There are also many 
unanswered questions regarding the mechanism of FGF signaling itself. For example, 
why Fgf10 is particularly potent in inducing ectopic ocular gland, while other Fgfs, such 
as Fgf1, lack such activity [18, 19, 41].  This can not be entirely explained by the 
specificity of Fgf10 to interact with Fgfr2b, because Fgf1 is also capable of activating the 
same receptor. Downstream to Fgf receptor, there are multiple intracelullar pathways, 
including Ras-MAPK, PI3K-AKT and PLC-PKC signaling. The specific roles of these 
pathways and their downstream targets are also important questions for future 
investigation. 
 
1.1.4.6 Transcriptional network in lacrimal gland development 
While signaling pathways provide the overall guidance of lacrimal gland morphogenesis, 
transcription factors are the ultimate interpreters and executors of the developmental 
program. The paired-domain transcription factor Pax6 is considered the master regulator 
of eye development [42]. Its expression precedes the budding of the lacrimal gland in the 
fornix of the conjunctival epithelium and continues in the lacrimal gland epithelium 
throughout development. Loss of function mutation in even a single allele of Pax6 results 
in severe impairment in mouse lacrimal gland development, suggesting that Pax6 serves 
as a competence factor in the epithelium [15]. In fact, detailed characterizations of Pax6 
enhancers have led to the development of the Le-Cre transgene, which can act as both a 
Cre deletor and reporter in the lacrimal gland epithelium, greatly facilitating the genetic 
analysis of lacrimal gland development [29, 43].  Surprisingly, lacrimal gland defects 
have not been reported in human aniridia (OMIM 106210), a congenital disorder caused 
by heterozygous mutation in PAX6.  Instead, patients with otofaciocervical syndrome-2 
carrying homozygous mutation in PAX1 (OMIM 615560) display lacrimal duct 
abnormalities, a phenotype shared with the closely related otofaciocervical syndrome-1 
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(OMIM 601653) that harbors mutations in EYA1 gene [44]. On the other hand, 
branchiootorenal syndrome-1 (BOR1, OMIM #113650) caused by heterozygous EYA1 
mutation and branchiootic syndrome-3 (OMIM #608389) cause by SIX1 heterodeficiency 
display many overlapping phenotype including lacrimal gland stenosis, suggesting that 
these two genes also act in the same genetic cascade.  In mouse, Six1 is widely expressed 
in the head mesenchyme during early development and it is also found in the duct and 
acini of mouse lacrimal gland [45]. Six1 knockout embryos exhibit small lacrimal glands 
with poor duct elongation and reduced branching, confirming the functional importance 
of Six1 in lacrimal gland development. From Drosophila to mammals, Pax, Six and Eya 
genes have been shown to form a conserved transcriptional network in organogenesis. It 
would be interesting to investigate whether these interactions still occur in lacrimal gland 
development.  
 
Whereas Pax/Six/Eya genes serve as competence factor for lacrimal gland development, 
additional transcription factors are required to specify the identity of the epithelium. 
TP63 is a transcription factor important for a variety of epithelial structures [46]. 
Mutations in this gene abolish lacrimal gland in mice and cause Limb-mammary 
syndrome (OMIM 603543) in humans, which presents lacrimal-duct atresia and 
obstructed lacrimal puncta [47]. Otx1 is a homeodomain transcription factor expressed in 
the conjunctival epithelium and Otx1-/- mice also fail to develop lacrimal gland [48]. In 
addition, loss of the epithelial gene, Runx1, resulted in a delay in embryonic lacrimal 
gland development as shown by reduced branching and smaller bud at E16.5. It is likely 
that Runx1 is compensated by Runx2 and Runx3, which are also expressed during 
lacrimal gland development [49].  
 
There are transcription factors that may regulate development of both epithelial and 
mesenchymal compartments of lacrimal gland. The majority of patients carrying 
heterozygous mutations in SOX10 (Waardenburg syndrome, OMIM 611584 and 613266) 
have hypoplastic or no lacrimal gland, underscoring the requirement of SOX10 for 
lacrimal gland genesis [50]. This finding corroborates with lacrimal gland defects in mice 
with conditional deletion of Sox10 in the epithelium [33]. However, Sox10 is also 
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expressed by migratory neural crest cells, which eventually form the periocular 
mesenchyme. It is possible that human systemic SOX10 mutation may also indirectly 
affect lacrimal gland induction by disrupting neural crest migration and differentiation. 
Similarly, TFAP2a mutations carried by Branchiooculofacial syndrome patients cause 
lacrimal duct obstruction phenotype (OMIM #113620). Because Ap2a is expressed in 
both neural crest and the surface ectoderm, we predict that TFAP2a function may be 
required in both the mesenchyme and epithelium of the lacrimal gland. These findings 
have been summarized in Table 1.  
 
1.2 Fgf signaling pathway 
1.2.1 Fibroblast growth factors and Fibroblast growth factor receptors 
Fibroblast growth factor family consists of 22 growth factors, dividing into seven 
subfamilies. Among them, six subfamilies are categorized as secreted Fgfs and one 
subfamily is intracellular Fgfs. Of these secreted Fgfs, five subfamilies (Fgf1, Fgf4, Fgf7, 
Fgf9, Fgf8) bind to their cognate Fgf receptors, with heparin/heparan sulphates in the 
extracellular matrix as co-receptors to limit the diffusion of Fgfs, and hence regulate the 
signal transduction. Another subfamily (Fgf15/19/21) comprises of endocrine Fgfs which 
have reduced binding affinity for heparan sulphates and they have been evolved to bind 
to cognate receptors with α/ß-Klotho, KLPH as co-receptors [51]. On the other hand, 
Fgf11 subfamily comprises of intracellular Fgfs (iFgfs) which are non-signaling proteins 
and they have been known to interact with intracellular proteins including voltage gated 
Na-channels and tubulins [52, 53].  
 
Fgf receptors are ~800 aa proteins containing three extracellular immunoglobulin 
domains (I, II, III), one transmembrane domain and two intracellular tyrosine kinase 
domains.  There are four such types of Fibroblast growth factor receptors. FGFR1, 
FGFR2, FGFR3, FGFR4. FGFR1-3 each have two splice variants via alternative splicing 
from the immunoglobulin domain III (IIIa, IIIb). A fifth FGF receptor, FGFRL1, have 
been discovered, which lacks the intracellular tyrosine kinase domain and hence, acts as a 
decoy receptor or modulator of Fgf signaling. These receptors have varying affinities for  
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Table 1: Transcription factors implicated during lacrimal gland development and 
maintenance. 
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Fgfs for conferring specificity and regulation of Fgf signaling in different tissue types 
[51]. 
 
1.2.2 Downstream signaling molecules and transcription factors 
Upon binding of Fgf ligand to Fgfrs, the receptors dimerized to trigger trans- 
autophosphorylation of the kinase domain.  Once Fgf signaling is activated, it has been 
shown to induce Ras/MAPK pathway involved in cellular proliferation and 
differentiation; PI3K/AKT pathway in cell survival and cell fate determination; PLCγ 
associated with cell morphology, migration and adhesion and signal transducer and 
activator of transcription (STAT) pathway implicated in different processes depending 
upon the cell context [54].  
 
For Ras-MAPK activation, relay of downstream signaling proteins is summarized in Fig. 
4. Fgf signaling is mediated by phosphorylation of FGFR substrate 2α (Frs2α). Frs2α is 
an adaptor protein which is normally anchored to the plasma membrane through 
myristoylation and is constitutively docked to the highly conserved FGFR binding site 
close to the membrane [55, 56]. Phosphorylated Frs2α recruits another adaptor protein 
Growth factor receptor bound-2 (Grb2) and tyrosine phosphatase, Src- homology protein 
2 (Shp2) [57]. 
 
The exact mechanism of how Shp2 regulates Fgf signaling is still debated in the field. In 
addition to its SH-2 domains, the catalytic activity of tyrosine phosphatase is found to be 
critical for Shp2 to mediate Fgf signaling, but the direct substrates of Shp2 are not clear. 
Several mechanisms have been proposed by which Shp2 can function, such as 
dephosphorylating RasGap and preventing its recruitment to receptor kinases, regulating 
Src-family kinases, or modulating the inhibitory function of Sproutys by 
dephosphorylating these proteins [58]. It is likely that Shp2 acts through one or more of 
these mechanisms in a context-dependent manner. 
 
Grb2 recruits Ras-GTPase to the plasma membrane through guanine nucleotide exchange 
factors (GEF), son of sevenless (SOS). Ras-GTPase activates Raf-kinases 
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phosphorylating mitogen activated protein kinase kinase (MAPKK/MEK) which 
phosphorylates mitogen activated protein kinase (MAPK/ERK). Activated Erk 
translocates to the nucleus to phosphorylate E26 transformation-specific (ETS) factors 
[59]. More specifically, Pea3 subfamily of transcription factors, Etv1/Er81, Etv4/Pea3 
and Etv5/Erm are often considered as downstream effectors of Fgf signaling [60, 
{Firnberg, 2002 #108, 61, 62]. 
 
Fgf signaling is regulated by inhibitory signaling molecules such as Sprouty, Dusps, Sef 
and CBL as negative feedbacks. Sprouty proteins bind to Grb2 and inhibit the recruitment 
of Grb2-Sos complex required for Ras-MAPK activation [63]. Dusp6 (Dual specificity 
phosphatase 6) directly dephosphorylates MEK when MEK is bound to its substrate Erk2 
[64]. Sef (similar expression to Fgfs) which belongs to the fibroblast growth factor syn-
expression group was found to inhibit Ras-MAPK pathway during zebrafish 
embryogenesis and in mammalian cultures [65, 66]. Later, it was demonstrated that Sef 
acted by preventing the dissociation of ERK from MEK [67] or preventing 
phosphorylation of FGFR [68]. CBL, an E3 ubiquitin ligase, forms a complex with Frs2α 
and Grb2 resulting in the ubiquitination and degradation of Fgfr and Frs2α, thus 
inhibiting Ras-MAPK pathway [69].  
 
1.2.3 Pea3 family of transcription factors 
Fgf signaling cascade stimulates the phosphorylation of Erk, resulting in its translocation 
to the nucleus to induce the expression of Pea3 family of transcription factors. Similar to 
Fgf signaling, these factors have been shown to be active at the sites of the epithelial to 
mesenchymal interaction during organogenesis, with Pea3 and Erm specifically 
exhibiting overlapping expression pattern in various tissues [70]. Interestingly, these 
Pea3 genes also act as oncogenes as they have been implicated in many cancers 
mimicking oncogenic RAS-MAPK pathways in melanoma, breast, lung and prostate 
cancer [71]. Conditional inactivation of Pea3/Erm in the lung epithelium caused 
increased mesenchymal Fgf10 expression and decrease in epithelial Shh expression, 
resulting in a smaller lung size and branching defects, however, mice were grossly 
healthy and exhibited normal life-span [72, 73]. Similarly, in the limb buds, Pea3/Erm 
 19
can mediate Fgf signaling in the proximal-distal (P-D) limb patterning as well as 
promoting and inhibiting Shh expression in the posterior and anterior limb bud 
respectively, as evident by growth defect along the P-D axis and mild preaxial 
polydactyly along the A-P axis with the mesenchymal loss of Pea3/Erm [74, 75]. In 
contrast to mild developmental defects in the lung, limb and mammary gland, Pea3/Erm 
are found to be downstream targets of Ret signaling, and they are absolutely necessary 
for kidney development, lack of which caused renal agenesis and hypoplasia [76]. 
Notably, among Pea3 factors, Er81 doesn’t add to the severity of the phenotype and 
cannot compensate for the loss of Pea3/Erm, highlighting its redundancy. These data 
show that Fgf signaling induces the transcription of Pea3 members and the extent of their 
functional relevance varies between the tissues. Although Pea3 transcription factors are 
expressed during development of lacrimal gland as reported previously [25, 32], the 
functional relevance of downstream Pea3 genes are yet to be investigated. 
 
1.2.4 Physiological role of Fgf signaling 
1.2.4.1 Embryogenesis 
FGF signaling pathway plays an important role in early embryogenesis during 
gastrulation. Fgfr1 knockout mice exhibit reduced proliferation and mesodermal cell fate 
specification defects [77, 78]. Similarly, Fgf8 knockout mice are embryonically lethal as 
they fail to form the mesodermal-derived tissues [79]. In later studies, Fgfr1 has also been 
shown to regulate migration and specification of the mesodermal progenitor cells at the 
primitive streak [80]. In Xenopus, studies have shown that FGF2, 4, 8 play roles in the 
mesoderm specification downstream of Nodal and Activin signals [81]. Fgf signaling has 
also been implicated during neural induction in the dorsal ectoderm by inhibiting the 
expression of BMPs [82].  
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Figure 4. Schematic of Ras/MAPK-mediated FGF signaling pathway. 
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1.2.4.2 Epithelial-Mesenchymal interactions 
In later stages, Fgf signaling has also been studied in the epithelial-mesenchymal 
interactions during limb development where the mesenchyme is derived from the 
mesoderm. Fgfr1 and 2 are expressed in the underlying mesenchyme which secretes 
Fgf10 to signal to the epithelium. As a result, Fgf8 is secreted by the epithelium to act on 
the mesenchyme to continue the expression of Fgf10 [83, 84]. During lung development, 
the mesodermal mesenchyme expresses Fgfr1 and Fgfr2 which respond to Fgf9 secreted 
by the lung epithelium to maintain the mesenchymal proliferation and Fgf10 expression, 
the latter signaling back to the epithelium to promote branching morphogenesis [85, 86]. 
Similarly, the mesoderm-derived pancreatic mesenchyme express the Fgfr2c isoform 
which binds to Fgf9 expressed by outer mesothelial lining of the mesenchyme [87]. 
Similar to lacrimal gland development as described in earlier section, the salivary gland is 
another example of the epithelial to mesenchymal interaction where the mesenchyme is 
derived from the cranial neural crest cells [88]. In this case, Fgf10 present in the 
mesenchyme is important for gland initiation and its expression is modulated by the 
ectodermal Fgf8 [89].  
  
1.2.4.3 Fgf signaling in the neural crest 
The neural crest is a multipotent stem cell population unique to vertebrates. It plays a 
critical role in the development of many different tissues including craniofacial 
structures, smooth muscle, ganglia of peripheral nervous system, adipose cells and 
melanocytes [90]. Neural crest is induced after gastrulation i.e.  formation of three germs 
layers is completed. Upon induction at the neural plate border between the neural plate 
and non-neural ectoderm, the neural crest undergoes definitive specification as neural 
plate folds [91]. These cells then migrate to different regions of the embryo depending 
upon where they lie on anterior-posterior axis, guided by the signaling cues in the 
environment [92, 93]. These cells then differentiate into distinct cell types as they reach 
their destination, depending upon their origin. Signaling relay between neural crest cells 
and surrounding organ primordia not only influences the differentiation and patterning of 
the neural crest cells but also of the interacting tissues [94]. Because of its involvement in 
the formation of diverse array of tissues, neural crest cells are designated as the  fourth 
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germ layer in the development biology field, in addition to the ectoderm, endoderm and 
mesoderm [95]. The research interest in studying signaling pathways in the neural crest 
stems from not only its extent of developmental contribution but also its implication in 
wide range of human diseases associated with defects in the heart, vision, facial structure, 
pigmentation, hearing, central nervous system and certain forms of cancer such as 
neuroblastoma [96].  
 
It is reasonable to speculate that Fgf signaling is important for the neural crest-derived 
mesenchymal function during lacrimal gland development. Neural crest -specific deletion 
of Shp2 has revealed that it plays an important role in migration and differentiation of 
neural crest cells during heart and skull development, mediated by Erk phosphorylation 
[97]. In support of this finding, another study showed that Raf/Mek/Erk/Srf regulation is 
critical for development of the neural crest-derived craniofacial structures and cardiac 
outflow tract [98]. 
 
1.2.4.4 Fgf signaling as cell fate determinant for lacrimal gland epithelium 
Fgf signaling is considered as important cell fate determinant mechanism during lacrimal 
gland development as ectopic expression of rat Fgf10 or human FGF7 in the cornea led 
to the switch in cell fate from the planar corneal epithelium to the secretory lacrimal 
gland epithelium [18, 19]. However, the key early response transcriptional factors which 
determine the lacrimal gland cell fate are still unclear. Previously, Sox transcription 
factors- Sox9 and Sox10, have been found to be downstream of Fgf signaling important 
for lacrimal gland development. Epithelial Sox9 is critical for induction of lacrimal gland 
and regulates Sox10 expression for acini formation at later stages [33]. However, it is not 
clear what are the direct transcriptional targets of Fgf signaling which regulate this 
process to establish Fgf signaling as an important cell fate determinant. 
 
1.3 Hypotheses 
1.3.1 Hypothesis #1 
Fgf signaling plays an important role for lacrimal gland development. This process is 
primarily induced by growth factor Fgf10, present in the neural crest cells forming the 
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peri-ocular mesenchyme which bind to its cognate receptor Fgfr2 and co-receptor 
heparan sulphates in the conjunctival epithelium, triggering the activation of Fgf 
signaling cascade. However, there are several unanswered questions on how this process 
is accomplished. One of the questions which is still unaddressed is the mechanism by 
which Fgf10 is produced by the neural crest cells in the mesenchyme. Since Shp2 
mediating Ras-MAPK signaling pathway is important for neural crest development and 
Fgf signaling pathway is frequently mediated by Shp2/Ras/MAPK, we hypothesized that 
Shp2- mediated Fgf signaling pathway is important for neural crest development to 
produce Fgf10 in the mesenchyme. To test this hypothesis, we used mouse models as 
lacrimal gland development in rodents which is very similar to what is present in humans. 
To specifically target the neural crest- derived mesenchyme, we used Wnt-1 Cre mouse 
line to conditionally delete genes within neural crest cells that are implicated in the 
canonical Fgf signaling pathway. To further investigate downstream targets of Shp2, we 
performed high throughput RNA-seq analysis of mesenchymal tissue in control and 
Shp2-ablated mouse embryos. 
 
1.3.2 Hypothesis #2   
It has been shown that Fgf signaling is critical for determining the fate of lacrimal gland 
cells as ectopic expression of rat Fgf10 and human FGF7 in the cornea, led to switching 
of the corneal fate to the glandular cell type.  However, direct downstream targets of Fgf 
signaling which determine the fate of lacrimal gland epithelial cells are still unknown. 
Since Pea3 transcription factors are direct downstream effectors of Fgf signaling and are 
expressed in the lacrimal gland epithelium as shown previously, we hypothesize that 
Pea3 transcription factors are direct effectors of Fgf signaling which mediate the cell fate 
determination. To test this hypothesis, we used mouse models to genetically ablate Pea3 
genes Erm and Er81 in the lacrimal gland epithelium using Le-Cre transgenic mouse line 
in Pea3-null background and determine their role during lacrimal gland development. In 
order to further determine the gene regulatory network downstream of Pea3 transcription 
factors, we performed RNA-seq analysis of lacrimal gland in control and Pea3-deficient 
mutant mouse embryos.  
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2 Materials and Methods 
2.1 Mice and Genotyping 
Mice carrying Erk1-/-, Erk2flox, Frs2αflox, Frs2α2F, Mek1flox, Mek2KO, Shp2flox alleles were 
bred and genotyped as described [98-102]. We obtained Etv1flox mice from Dr. Silvia 
Arber (University of Basel, Basel, Switzerland), Etv4-/- and Etv5flox mice from Dr. Xin 
Sun (University of California at San Diego, San Diego, CA), En1-Cre and R26-EtvEnR 
from Dr. James Li (University of Connecticut Health Center, Farmington, CT), Fgf8flox 
from Dr. Suzanne Monsour (University of Utah, Salt Lake city, UT), Fgf15-/- from Dr. 
Steven Kliewer (UT Southwestern Medical Center, Dallas, TX), Fgfr1∆Frs from Dr. Raj 
Ladher (RIKEN Kobe Institute-Center for Developmental Biology, Kobe, Japan), Fgfr2LR 
from Dr. Jacob V.P. Eswarakumara (Yale University School of Medicine, New Haven, 
CT) and Fgfr2flox from Dr. David Ornitz (Washington University Medical School, St 
Louis, MO) [74, 75, 103-109]. LSL-KrasG12D mice was obtained from the Mouse Models 
of Human Cancers Consortium (MMHCC) Repository at National Cancer Institute [110]. 
Alx4lst-J (Stock No: 000221), Fgfr1flox (Stock No: 007671), p53flox (Stock No: 008462), 
Pdgfrαflox (Stock No: 006492), R26R (Stock No: 003474), R26RTdT (Ai14, Stock 
No: 007914), Sox10-Cre (Stock No: 025807) and Wnt1-Cre (Stock No: 009107) mice 
were obtained from Jackson Laboratory [108, 111-116]. Le-Cre mice were kindly 
provided by Dr. Ruth Ashery-Padan (Tel Aviv University, Tel Aviv, Israel) and Dr. 
Richard Lang (Children's Hospital Research Foundation, Cincinnati, OH). Rosa-N1-
ICDflox/+ mice were obtained from Jackson lab (Stock # 008159). Animals were all 
maintained on mixed genetic background. Wnt1-Cre, Le-Cre, Shp2flox and Pea3+/-
/Ermflox/Er81flox only mice did not display any lacrimal gland phenotypes and were used 
as controls.  Mice were housed in virus-free facility in a 12 hour light-dark cycle and 
were given standard mouse feed. 
 
2.1.1 Embryo collection 
Females in breeding were checked for vaginal plugs which are considered 0.5 days pc. 
Embryos were harvested in 1XPBS at appropriate days based on the experiment and 
taken out of embryonic sac. Embryos were then fixed in 4%PFA or flash frozen in OCT 
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depending upon the experimental condition. For genotyping, embryonic tail samples were 
collected and stored in -20°C until processing. 
 
2.1.2 Genotyping 
For breeding strains and identifying embryos, tail samples were collected and heated in 
300 µl of 50nM NaOH for 1 hour at 95ºC to release the DNA in solution. These samples 
were then neutralized with 17.1 µl of 1M Tris HCl, pH 8.0 and centrifuged at 13,000 rpm 
for 3 min. The supernatant was used as template for PCR reaction. PCR conditions for 
10ul reaction are as follows. 10X PCR buffer mix- 1 µl, Primers, F and R – 0.1 µl each, 
DNA Template- 1 µl, Taq- 0.2 µl. PCR buffer mix was made in house with the addition 
of dNTPs and tracking dye. 
 
2.2 Histology  
Hematoxylin and Eosin staining (H&E) is performed as previously described [32]. 
Briefly, paraffin blocks were sections at 10 µm and were deparaffinized by heating and 
performing series of histosol washes (3 X 5 min), followed by rehydration by treating the 
slides through decreasing percentage of ethanol solutions (100% - 2X 3 min, 95% 
ethanol- 2 X 3 min, and 70% ethanol- 1 X 3 min). The slides were dipped into 
hematoxylin for 3 min followed by 10-15 min wash with tap water. The samples were 
decolorized with 1% acid alcohol for 15 sec, before dipping in Eosin solution for 1min. 
Samples were then dehydrated by passing through increasing concentration of ethanol, 
and transferred to histosol. The stained slides were mounted with cover-slips using 
PermountTM mounting medium.  
 
2.3 Immunohistochemistry 
For immunohistochemistry of paraffin samples, sections were deparaffinized and 
rehydrated by serial treatment with histosol followed by decreasing percentage of ethanol 
solutions (2X 100 %, 2 X 95%, 1X 70% for 5 min each). For cryosections, sections were 
briefly washed with PBS to remove OCT medium (Sakura). Antigen retrieval was 
performed with microwave boiling for 1-2 minutes followed by heating for 10 minutes at 
low power settings in citrate buffer (10 mM sodium citrate, pH 6.0). Sections were then 
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washed with PBS and blocked with 5% NGS/0.1% Triton in PBS. Primary antibody 
incubation was performed overnight at 4°C in humid chamber followed by incubation 
with florescent-conjugated secondary antibodies for 1 hour at room temperature in dark. 
For signal amplification, HRP-conjugated secondary antibodies are used, followed by 
washing and equilibration with TNT buffer. The slides were then incubated with 
Tyramide reagent for 10 min, washed with TNT buffer, stained with DAPI and mounted 
with anti-fade reagent, 0.2% NPG, 90% glycerol in 1X PBS. Following antibodies with 
respective dilutions were used as shown in Table 2. 
 
 2.4 Carmine staining 
For carmine staining, post-natal P1-3 heads were decapitated and cheek skins were 
removed to expose lacrimal gland. Embryos were fixed in 4% PFA O/N at 4ºC, washed 
with PBS and transferred to 70% ethanol for O/N incubation at 4ºC. Embryo heads were 
stained in aceto-carmine for 5 minutes, 70% EtOH for 3 minutes, 1% Acid-EtOH for 2 
minutes, 5% Acid-EtOH for 1 minute. To de-stain, 95% ethanol was used.  Recipe for 
Aceto-carmine staining reagents: Aceto-carmine: 0.5gm carmine stain (SIGMA), 100 ml 
boiling 45% acetic acid; 1% Acid-EtOH: 1.0ml HCl, 100ml 70% EtOH; 5% Acid-EtOH: 
5.0ml HCl, 100ml 70% EtOH. 
 
2.5 X-gal staining  
E13.5 embryos were incubated in 4% PFA for 1 hour at 4ºC and washed twice in PBS 
containing 0.02% NP-40, 0.01% sodium deoxycholate and 2 µg/ml MgCl2 for 30 min 
each, followed by overnight incubation in X-gal staining solution (1 mg/ml X-gal, 10 
mM Potassium Ferricyanide, 10nM Potassium Ferrocyanide, 2 µg/ml MgCl2 in PBS) at 
4ºC.  The samples were then cryopreserved in OCT (Sakura Finetek), sectioned at 10 µm 
thickness and counter-staining with nuclear red. 
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Table 2: List of antibodies, catalog number and dilutions. 
 
 
 
2.6 RNA in situ hybridization 
2.6.1 Whole mount format 
Whole mount in situ hybridization was performed as previously described [117]. Briefly, 
embryos were harvested in DEPC-PBS, fixed overnight in 4%PFA and dehydrated in 
graded solutions of 25%-100% methanol in PBS and stored in -20°C. On the day of 
experiment, embryos were rehydrated with decreasing concentrations of methanol in 
PBS. Embryos were then treated with Proteinase K at 10 µg /ml for 3-10 min at room 
temperature depending upon the stage, followed by quenching with 2mM glycine. 
Embryos were treated with RIPA buffer and additionally fixation in 2% glutaraldehyde, 
followed by washing in PBS and incubation in hybridization buffer at 65°C for 1 hour. 
Next, embryos were hybridized with diluted probe (1:1000) in hybridization buffer with 
Antibodies Catalog number Dilution 
 Pax6  PRB-278P, Covance, Berkeley, CA, 
USA 
1:250 
RFP 600-401-379, Rockland 1:1000 
Alx4 sc-33643, Santa Cruz Biotechnology 1:100 
E-cadherin U3254, Sigma, St Louis, Missouri 1:200 
Cleaved-caspase 3 #9664, Cell signaling Technology 1:200 
Col2a1 ab34712, Abcam 1:200 
Connexin43 #3512, Cell signaling Technology 1:200 
pHH-3  #06-570, Millipore 1:500 
α-SMA  #C6198, Sigma-Aldrich 1:200 
N1-ICD Cell signaling 1:200 
Jag1 sc-8303, H-114, Santa Cruz 
Biotechnology 
1:200 
Krt14 Covance, PRB-155P  1:1000 
p-Erk Cell signaling #4370 1:200 
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r-RNA (10 µg/ml) and incubated at 68°C overnight. The embryos were washed 8-10 
times with 1x SSC and 50% formamide at 65°C, equilibrated with maliec acid buffer and 
blocked with anti-DIG antibody (Roche, 1:5000). Embryos were washed for 2-3 days 
with TBST and equilibrated with alkaline phosphatase buffer for 1 hour prior to 
incubation with AP-substrate BM purple (Roche) for several days at 4°C for color 
development.  
 
2.6.2 Sectional format 
RNA in situ hybridization was performed as previously described [118]. Briefly, the 
mouse embryos are harvested, fixed overnight in 4%PFA, equilibrated in 30% sucrose 
and cryo-frozen in OCT. On the day of the experiment, OCT blocks are sectioned at 10 
µm and hybridized with diluted probe at 68°C overnight in a wet chamber, moistened 
with solution containing 50% Formamide and 1X Salt. Probe is diluted 1:200-500 in pre-
warmed hybridization buffer and incubated at 70°C for at least 10 min. Next day, the 
slides were washed 3X in wash buffer (1X SSC, 50% Formamide) at 68°C. After cooling, 
slides were washed 2X with 1X MABT and incubated at room temperature for 30 min. 
Slides were blocked with 20% Sheep serum in 1XMABT for 1 hour, followed by 
incubation with anti-DIG antibody (1:1500) at 4°C for overnight. Next day, slides were 
washed 4-5X with 1X MABT and 2X with alkaline phosphatase buffer. For color 
development, slides were covered with BM purple substrate and incubated at room 
temperature for 4-24 hrs. 
 
2.6.3 Probes 
 The following probes were used: Alx1 (from Dr. Terence Capellini, Harvard University, 
Boston, MA), Alx4 (from Dr. Yang Chai, University of Southern California, Los Angeles, 
CA), Pea3/Etv4, Erm/Etv5 (from Dr. Bridget Hogan, Duke University Medical Center, 
Durham, NC, USA), Foxc1, Sox10, Crabp1 (from Dr Anthony Firulli, Indiana University 
School of Medicine, Indianapolis, IN, USA), Fgf10 (for whole mount) (from Dr. Suzanne 
Monsour, University of Utah, Salt Lake city, UT)), Fgf10 and Dusp6 (for sections) was 
generated from a full length cDNA clone (IMAGE: 6313081 and 3491528, Open 
Biosystems, Huntsville, AL, USA), Pitx2 (from Dr. Valerie Dupé, CNRS, Strasbourg, 
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France), Six1 (from Dr. Bernice Morrow, Albert Einstein College of Medicine), Six2 
(from Dr. Thomas Caroll lab, UT Southwestern Medical center), Er81 (from Dr. Fischell, 
NYU Lagnone Medical Center). 
 
2.7 Laser capture micro-dissection and Gene expression profiling 
Freshly harvested embryos were frozen in OCT medium (Sakura Finetek), sectioned at 
10 µm thickness and transferred to PEN slides (Ziess), which can be stored in -80°C 
under dry conditions (with silica beads in the tube) until further processing. For staining, 
slides were dipped in ice cold 95% ethanol for 2 min to fix the samples, stained with 
crystal violet stain (Stock- 3% in ethanol diluted in ethanol and Tris HCl pH 8-8.5 in 
6:5:3.85) for 1 min on ice. The slides were then dipped 2X in ice cold 70% ethanol for 
30-40 sec to remove the OCT and dehydrated in ice cold 100% ethanol for 2 min. For 
control and Pea3/Etv mutant embryos, lacrimal gland epithelial tissue was micro-
dissected using Laser capture microscope (Zeiss AxioObserver.Z1 inverted microscope). 
For Pea3 conditional knockout experiment, RNA was extracted using Qiagen Micro Plus 
kit. Conversion to cDNA and amplification was performed using Clontech SMART-seq 
v4 Ultra low input RNA kit, as well as cDNA library construction was performed using 
Nextera XT DNA library preparation kit by core facility at Columbia university prior to 
RNA sequencing. On the other hand, for Shp2 conditional knockout experiment, 500 pg 
of RNA was isolated from each sample, converted to cDNA and amplified using Nugen 
Ovation kit v2 (Nugen) to obtain 2-3 μg cDNA, which was then converted to cDNA 
library for RNA-sequencing analysis at core facility in Columbia University.  
 
2.8 Lacrimal gland mesenchyme culture  
Lacrimal glands mesenchymal culture was performed as described  previously [119].  
Briefly, glands were isolated from P0-P2 pups and trypsinized (Gibco 1:250) at 4 ºC for 1 
hr. After neutralizing trypsin, the mesenchyme was manually separated from the 
epithelium using fine needle and grown in the complete medium (DMEM+10% FBS with 
antibiotics) for 3 days before passage. The primary mesenchymal cells were transfected 
with siRNA using Lipofectamine RNAimax as previously described and harvested after 
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24-48 hrs [120]. For Alx1 and Alx4, the results were confirmed using two different 
predesigned Silencer® Select siRNAs from Ambion (Life technologies).  
 
2.9 Quantitative-PCR (qPCR) 
Quantitative-PCR was performed as described [121]. Briefly, total RNA was extracted 
from MiniRNA Plus kit from Qiagen and converted to cDNA using High-Capacity 
cDNA Reverse Transcription Kit from Applied Biosystems. PCR SYBR green 2X master 
mix was used from Applied Biosystems and analyzed on StepOne plus Real time PCR 
instrument. Following primers were used. Alx4: 5’-ACACATGGGCAGCCTGTTTG3’, 
5-TGCTTGAGGTCTTGCGGTCT-3’, Alx1: 5’ GGAGGAAGTGAGCAGAGGTG-3’, 
5’- TTCAAATGCGTGTCCGTTGGT-3’, Fgf10:  5’ CAATGGCAGGCAAATGTATG-
3’, 5’- GGAGGAAGTGAGCAGAGGTG-3’, Gapdh: 5’-
AGGTCGGTGTGAACGGATTTG-3’, 5’-TGTAGACCATGTAGTTGAGGTCA-3’, 
Shp2 (exon 4): 5’- CTGACGGAGAAGGGCAAGCA-3’, 5’- 
CGCACGGAGAGAACGAAGTCT-3’ 
 
2.10 Chromatin Immunoprecipitation 
The Chromatin Immunoprecipitation (ChIP) assays were performed in 3T3 fibroblasts 
cells and primary lacrimal gland mesenchymal cells as described [122]. Briefly, the cells 
grown in DMEM/10% FBS with antibiotics were crosslinked with 1% Formaldehyde for 
8-10 min with gentle shaking. This was followed by quenching with 125 mM glycine or 5 
min, 3X washing with cold PBS and addition of 1 ml of cold CHIP lysis buffer. After 
incubation for 10 min at 4°C, the lysed cells were centrifuged at 3000 rpm for 3 min and 
the pellet were stored at -80°C until later use. The pellet was then re-suspended in 1.2 ml 
of RIPA buffer, sonicated on ice for 8 min using probe sonicator (1 sec “on”, 2 sec “off”, 
power 3.5) and centrifuged at 13000 rpm for 15 min at 4ºC. The supernatant was 
precleared by adding 45 µl Protein G agarose beads (50% slurry, Millipore) and 
incubated for 2 hours at 4°C on rotor. After centrifugation at 5000 rpm for 1 min, the 
supernatant was transferred to a fresh tube and the protein concentration was measured 
by Bradford assay. For pull down, 1 μg of antibodies were added per 1mg of protein for 
overnight incubation at 4°C, followed by addition of 20 µl agarose beads for another 1-2 
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hours incubation. After brief centrifugation, the beads washed 1X with RIPA buffer at 
room temperature, 3X with cold RIPA buffer, 2X with cold Wash buffer A and Wash 
buffer B, 1X with TE/150mM NaCl.  Next, the samples were decrosslinked in Elution 
buffer containing RNAase (40µg/ml) and Proteinase K (20µg/ml) for 1 hour at room 
temperature and 50°C overnight. After brief centrifugation, the supernatant was treated 
with equal vol. of Phenol/Chloroform and the DNA was precipitated with 2.5 vol. of 
100% ethanol and Glycoblue for 1 hour at -80°C and dissolved in 20 μl sterile water for 
qPCR analysis. The antibodies used were IgG as isotype control (sc-2028, Santa Cruz 
Biotechnology) and anti-Alx4 (sc-22066, Santa Cruz Biotechnology). Buffer recipes: 
CHIP lysis buffer- 10mM Tris-Cl, pH-8, 85mM KCl, 0.5% NP-40, 5nM EDTA, 0.25% 
Triton; RIPA- 1% Triton, 150mM NaCl, 0.1% SDS, 0.1%  Na-Deoxycholate, 10mM 
Tris-Cl, pH-8, 5mM EDTA; Wash buffer A- 50mM HEPES, pH7.9, 500mM NaCl, 1mM 
EDTA, 1% Triton, 0.1% Na-deoxycholate, 0.1% SDS, Wash buffer B- 20mM Tris-Cl, 
pH-8, 1mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate; Elution Buffer- 
1% SDS, 30 mM Tris-Cl (pH-8), 15mM EDTA, 200mM NaCl. Protease inhibitor 
cocktail is added prior to use in all the buffers until ready to elute. The primers used for 
CHIP in intron 1 of Fgf10- F- 5’-GGTTGGAGCTTGTTGTGTGT-3’, R- 5’-
GCTCTGCTAATAAAGGTCTCCC-3’. 
 
2.11 TUNEL assay 
TUNEL assays were performed on 10-μm paraffin sections following the manufacturer's 
instructions in the In Situ Cell Death Detection kit, Fluoroscein (Roche Applied Science, 
Indianapolis, IN). Cell proliferation and apoptosis rates were calculated as the ratio of 
phospho-histone H3 or TUNEL-positive cells to DAPI-positive cells in control and 
mutant samples, and results were analyzed by one-way non-parametric t-test.  
 
2.12 Bioinformatics analysis 
Scanning for Alx4 binding sites on Fgf10 gene- We retrieved 200 KB upstream and 100 
KB downstream of Fgf10 transcription start site from Mouse Genome assembly 
GRCm38/mm10 and analyzed this sequence for evolutionary conservation using UCSC 
genome browser. These sequences were also overlaid with the DNase-hypersensitivity 
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data from 3T3 cell line retrieved from ENCODE database and scanned for Alx4 
consensus binding sites based on TRANSFAC (release 2013.1) database using MATCH 
algorithm, with minFP as parameter to identity sites with minimum false positives.  
Analysis of RNA-seq data from Pea3 conditional knockout lacrimal gland:  Unsupervised 
clustering analysis was performed using MATLAB using Clustergram function. We 
determined interquartile ranges of the gene expression levels in all the samples and top 
200 genes were plotted. Gene set enrichment analysis (GSEA) was performed using 
MATLAB implementation of the same method as described in reference [123]. KEGG 
pathway enrichment analysis and functional annotation was performed in DAVID.  For 
the functional annotation of downregulated genes, list of 476 genes was used for the 
analysis based on cut off on normal expression level (> 50 units), Log2(fold change) (<-
1) and p-value (<0.05). Similarly, for the pathway analysis of upregulated genes, list of 
640 genes was used for the analysis (normal expression level >50, Log2FC >1, p-value 
<0.05).  Volcano plots representing Log2 (p-value) vs Log2(Fold change) were plotted in 
MATLAB. Log2(p-value)> 0.05 were set to 0.05 to avoid the scaling issues in the plot. 
“VennDiagram” library in R were used to generate Venn diagrams. To identify 
Er81/Etv1 and Pea3/Etv4 binding sites in the promotor region of genes, we retrieved 
1000 bp upstream from Mouse Genome with assembly GRCm38/mm10 using UCSC 
genome browser. These sequences were scanned for consensus Etv1/4 binding sites 
retrieved from TRANSFAC, release 2013.1 using MATCH algorithm, with minFP as 
parameters to identity sites with minimum false positives. Principal component analysis 
with the previously published skin gene expression data was performed using script 
written in MATLAB. 
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3 Results 
3.1 Alx4 relays sequential FGF signaling to induce lacrimal gland morphogenesis  
3.1.1 Lacrimal gland development requires FGF but not PDGF signaling in the 
neural crest  
FGF signaling is important for development of the neural crest derived craniofacial 
structures [51, 108, 124-128]. Using the neural crest specific Wnt1-Cre, we observed that 
conditional knockout of Fgfr1 resulted in significant craniofacial abnormalities, whereas 
deletion of Fgfr2 did not exhibit obvious effect (Fig. 5A, C and E, arrows). Lacrimal 
gland development begins with the invasion of an epithelial bud from the conjunctiva 
into the periocular mesenchyme at embryonic day 14.5 (E14.5) (Fig. 5B, arrow).  In 
Fgfr1 and Fgfr2 single mutants, lacrimal gland development was mostly unaffected (Fig. 
5D and F, arrows).  Combined deletion of both Fgfr1 and Fgfr2, however, abrogated 
lacrimal gland budding (Fig. 5G and H, arrows), indicating that Fgfr1 and Fgfr2 can 
compensate for each other in the neural crest during lacrimal gland development.  
Fgfr1ΔFrs and Fgfr2LR alleles encode the respective mutant Fgfr1 and Fgfr2 that lack the 
docking site for adaptor protein Frs2α [108, 109]. Although Fgfr2L/R homozygous mice 
were viable and fertile, the craniofacial and lacrimal gland phenotypes were observed in 
both Wnt1-Cre;Fgfr1 f/ΔFrs;Fgfr2 f/f and Wnt1-Cre;Fgfr1 f/f;Fgfr2 f/LR mutants (Fig. 5I-L, 
arrows).  The essential role of neural crest Frs2α for lacrimal gland development was 
further demonstrated in Wnt1-Cre;Frs2αf/f mutants, which displayed less severe 
craniofacial phenotype than Fgfr mutants, but similar arrest of lacrimal gland budding 
(Fig. 5M and N, arrows).  Finally, lacrimal gland development was also aborted in Wnt1-
Cre;Frs2αf/2F mutants, which carries mutation in two tyrosine residues in Frs2α 
(Frs2α2F) required for binding of Shp2 protein phosphatase (Fig. 5Q, n=6) [102].  In 
contrast, although Pdgfrα was expressed in the periocular mesenchyme and required for 
craniofacial development, its neural crest-specific knockout failed to impair lacrimal 
gland development (Fig. 5O-R, arrows).  These results demonstrated that lacrimal gland 
development specifically requires FGF-Frs2-Shp2 signaling in the neural crest. 
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3.1.2 Neural crest Shp2 regulates Fgf10 expression in the periocular mesenchyme 
for lacrimal gland development 
To investigate the downstream target of the neural crest FGF signaling for lacrimal gland 
development, we next generated Wnt1-Cre;Shp2f/f mutants, which lacked lacrimal gland 
as expected (Fig. 6A and B, dotted lines, n=6). Consistent with the idea that the neural 
crest is the main contributor of the periocular mesenchyme, immunostaining confirmed 
that Shp2 protein was depleted in the periocular mesenchyme, but preserved in the 
ectoderm-derived conjunctival epithelium (Fig. 6C and D, arrows and dotted lines).  
Although the epithelial cells maintained Pax6 and E-cadherin staining, there was no 
increase in Col2a1 expression, a hallmark of the nascent lacrimal gland bud (Fig. 6E-H, 
dotted lines).  By contrast, the periocular mesenchyme expression of Col2a1 was 
preserved, suggesting that the identity of these neural crest-derived cells was unchanged.   
 
The budding of lacrimal gland requires the inductive signal of Fgf10 emanating from the 
periocular mesenchyme.  In E13.5 control embryos, Fgf10 was found in a ring pattern in 
the presumptive eyelid surrounding the eye (Fig. 6I, arrowheads), with the strongest 
signal in the mesenchyme adjacent to the future lacrimal gland bud (Fig. 6I and K, 
arrows). In both Wnt1-Cre;Shp2f/f, however, Fgf10 was absent in the entire periocular 
mesenchyme (Fig. 6J and L, arrows and arrowheads). As a result, ERK phosphorylation 
was maintained in the adjacent retina but abolished in the conjunctival epithelium (Fig. 
6O and P, dotted lines), suggesting a specific loss of FGF signaling in the lacrimal gland 
primordia.  This was further supported by downregulation of FGF signaling response 
genes, Etv4 and Etv5, in the presumptive lacrimal gland epithelium (Fig. 6Q-T, dotted 
lines).  Considering the essential role of Fgf10 signaling in inducing lacrimal gland bud, 
we concluded that the lack of Fgf10 expression accounted for lacrimal gland aplasia in 
neural crest Shp2 mutants. 
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Figure 5. The neural crest specific ablation of Fgfr and Frs2α disrupted lacrimal 
gland. (A-N) Lacrimal gland budding occurred in Fgfr1 and Fgfr2 single, but not in 
double mutants (A-H, arrowheads). Mutation of Frs2α binding site on Fgfr1 (Fgfr1ΔFrs) 
or Fgfr2 (Fgfr2L/R) or deletion of Frs2α itself also disrupted lacrimal gland development 
(I-N, arrowheads). Note the severity of the craniofacial phenotype does not always 
correlate with lacrimal gland defects (compare C, D, M and N). Arrow: craniofacial 
abnormalities. Arrowheads: lacrimal gland primordia. e: eye. (O-P) Pdgfrα was 
expressed in the periocular mesenchyme (O, arrow), but its deletion in the neural crest 
did not affect lacrimal gland budding (P, arrow). (Q) Frs2α-Shp2 interaction is required 
for lacrimal gland development. In Wnt1-Cre;Frs2αf/2F mutant that disabled Shp2 binding 
to Frs2α, lacrimal gland development was aborted at E14.5 (n=6). (R) Quantification of 
lacrimal gland phenotype.  
 
Q 
 
R 
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The Wnt1-Cre transgene was recently reported to cause ectopic expression of Wnt1 in the 
midbrain-hindbrain boundary [129]. To ensure that this complication did not compromise 
our results, we used another neural crest-specific deletor Sox10-Cre to ablate Shp2, which 
also abolished lacrimal gland development, likely caused by Fgf10 expression in the peri-
ocular mesenchyme (Fig. 6U-X, arrows).  Altogether, there results showed that Shp2 in 
the neural crest is required for lacrimal gland budding in a non-cell autonomous manner. 
 
3.1.3 Ras-MAPK signaling and ETS transcription factors are downstream effectors 
of Shp2  
FGF signaling is known to activate the Ras family of small GTP-binding proteins, which 
play important roles in cell proliferation, migration and differentiation.  Previous studies 
have identified multiple downstream targets of Ras, including Raf kinases, type I 
phosphoinositide (PI) 3-kinases, Ral guanine nucleotide exchange factors, the Rac 
exchange factor Tiam1, and phospholipase C3 [130].  Among these molecules, Raf 
kinases activate the mitogen-associated protein kinase (MAPK) cascade that culminates 
at phosphorylation of Mek kinases (Mek1 and 2) and their direct targets Erk kinases 
(Erk1 and 2) [131].  At E10.5, ETS transcription factors Etv1, 4 and 5 were strongly 
expressed in tissues known to have active FGF signaling (Fig. 7A, arrows).  In both 
Wnt1-Cre;Shp2f/f and Wnt1-Cre; Mek1f/f;Mek2-/- embryos, these expressions were 
significantly down regulated in the cranial neural crest-derived mesenchyme in the 
midbrain, branchial arches and nose (Fig. 7A, arrowheads), supporting that Shp2 and 
Mek operate in the same signaling cascade leading to Etv1, 4, and 5 expression. 
Furthermore, lacrimal gland development never initiated after genetic removal of Mek1/2 
in the neural crest (Fig, 7B, arrowhead, n=8). Interestingly, however, a small lacrimal 
gland protrusion was seen in Wnt1-Cre; Erk1-/-;Erk2f/f embryos, suggesting that Mek may 
have additional key targets other than Erk (Fig. 7B, arrowhead, n=2) that participate in 
budding morphogenesis. Furthermore, by taking advantage of a conditional allele of 
oncogenic Kras (LSL-KrasG12D), we showed that constitutively active Ras signaling in the 
neural crest rescued Shp2 deficiency during lacrimal gland budding (Fig. 7B, arrows, 
n=10), supporting the downstream role of Ras-MAPK activation in the FGF-Shp2 
signaling cascade in the neural crest [132-135].   
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Figure 6.  Lacrimal gland budding requires Shp2 in the neural crest. (A-J) Wnt1-Cre 
mediated ablation of Shp2 in the neural crest resulted in loss of Shp2 staining in the 
periocular mesenchyme (A and B, arrows) and abrogation lacrimal gland buds at E14.5 
(C-D, dotted lines). The lacrimal gland primordia in Shp2 mutants still expressed Pax6 
and E-cadherin (E-F, dotted lines), but failed to upregulate Col2a1 and Sox10 expressions 
(G-J, dotted lines). (K-T) Fgf10 was normally expressed in the E13.5 periocular 
mesenchyme to induce downstream targets pERK, Etv4 and Etv5 in the lacrimal gland 
bud, but these were all down regulated in Shp2 mutants. Arrow: Fgf10 expression next to 
the future lacrimal gland bud. Arrowhead: Fgf10 expression in the eyelid mesenchyme. 
The lacrimal gland primordia were outlined with dotted lines. Shp2 deletion in the 
migratory neural crests disrupted lacrimal gland development. (U-V) Sox10-Cre mediated 
ablation of Shp2 in the migrating neural crest also abolished lacrimal gland budding at 
E14.5 (arrows). (W-X) Fgf10 expression was lost in the periocular mesenchyme 
(arrowheads). Lacrimal gland primordia are outlined with dotted lines. 
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The faithful expression of Etv1, 4 and 5 in response to Ras-MAPK activity prompted us 
to investigate the functional significance of these three transcription factors.  
Surprisingly, even combined inaction of Etv1/4/5 in the neural crest lineage failed to 
perturb lacrimal gland development (Fig. 7C, n=8), suggesting that these genes may be 
compensated by other ETS domain transcription factors that share similar binding 
specificity.  To overcome this genetic redundancy, we used a Cre-inducible transgene 
(R26-EtvEnR) to express Etv4 fused with the Engrailed repressor domain, which acts as a 
dominant negative ETS transcription factor [75].  Wnt1-Cre; R26-EtvEnR embryos not 
only exhibited craniofacial defect, but also showed reduced elongation of the lacrimal 
gland (Fig. 7D, n=8). This result suggests that ETS domain transcription factors are 
downstream effectors of FGF-Shp2-Ras-MAPK signaling in neural crest development. 
 
3.1.4 Lacrimal gland aplasia is not due to aberrant neural crest induction, migration 
and death 
FGF signaling has been implicated in the induction, proliferation, migration and 
differentiation of neural crest cells [125, 136-139]. The periocular mesenchyme 
originates from the neural tube in the midbrain, where active FGF signaling indicated by 
Etv5 expression coincides with Fgf8 expression (Fig. 8A, arrows), suggesting that Fgf8 
may activate FGF signaling during induction of cranial neural crest progenitors.  
Considering that Fgf15 is also expressed in the midbrain, we ablated Fgf8 in the 
midbrain-hindbrain junction using En1-Cre in the Fgf15 null background.  As expected, 
both Fgf8 and Etv5 midbrain expressions were absent in En1-Cre;Fgf8f/f;Fgf15-/- 
embryos (Fig. 8A, arrowheads), demonstrating a loss of FGF signaling. Nevertheless, the 
lacrimal gland bud still developed normally in these mutants (Fig. 8A, asterisks; n=3), 
showing that FGF signaling at the induction of the cranial neural crest is not required for 
lacrimal gland development. 
 
After induction at the dorsal neural tube, the neural crest progenitors express Sox10 as 
they begin to migrate toward their destination.  At E10.5, although Sox10-positive neural 
crest cells were present in the cranial mesenchyme in Wnt1-Cre;Shp2f/f mutants, their 
number and the extent of migration were slightly reduced as compared to those in the  
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Figure 7. Shp2 regulates MAPK-Etv signaling in the neural crest. (A) FGF signaling 
target genes Etv1, Etv4 and Etv5 were expressed in the midbrain-hindbrain junction, 
branchial arches and nasal placode. These expressions were reduced by deletion of Shp2 
and Mek1/2 in the neural crest. Arrows point to Etv-expressing regions in the brain. (B) 
Lacrimal gland budding was lost in Wnt1-Cre; Mek1f/f ;Mek2-/- and Wnt1-Cre; Erk1-
/-;Erk2f/f  mutants, but rescued by constitutive activation of Ras signaling in Wnt1-Cre; 
Shp2f/f; LSL-KrasG12D embryos. Arrow: lacrimal gland primordia. (C) Wnt1-Cre mediated 
deletion of Etv1, 4 and 5 failed to disrupt lacrimal gland development. (D) Expression of 
Etv4-Engrailed repressor (EnR) fusion protein in the neural crest led to craniofacial 
defects (arrow) and reduced lacrimal gland budding (arrowheads), ameliorated in Wnt1-
Cre;Shp2f/f;LSL-KrasG12D embryos (Fig. 7B, arrowheads), supporting a role for Shp2-
Ras-MAPK signaling in the post-inductive neural crest cells.   
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control embryos (Fig. 8B, arrows), suggesting that the loss of Shp2 produces subtle 
defects in neural crest proliferation and migration.  This phenotype was reproduced in 
Wnt1-Cre; Mek1f/f;Mek2-/- embryos, but ameliorated in Wnt1-Cre;Shp2f/f;LSL-KrasG12D 
embryos (Fig. 8B, arrowheads), supporting a role for Shp2-Ras-MAPK signaling in the 
post-inductive neural crest cells.  Previous studies in zebrafish suggested that Shp2 may 
have a MAPK-independent function in preventing p53-mediated apoptosis in the neural 
crest [134].  Using lysotracker dye to stain acidic lysosomes in cells undergoing 
apoptosis, we indeed observed extensive cell death in the first pharyngeal arch in E10.5 
Shp2 mutant embryos (Fig. 8C, arrows). In sections, cleaved-caspase 3 staining also 
detected abnormal cell apoptosis in the periocular mesenchyme, although the apoptotic 
regions were far removed from the conjunctiva (Fig. 8C, arrowheads).  We reasoned that 
if the apoptosis induced by Shp2 deletion was indeed dependent or partially dependent on 
p53, it may be reduced by removal of p53. However, ablation of p53 in Shp2 mutants 
failed to prevent cell death in the first pharyngeal arch or to rescue any craniofacial 
phenotype (Fig. 8C, arrows and arrowheads).  In lacrimal gland development, budding 
morphogenesis was still aborted in Wnt1-Cre; Shp2f/f;p53f/f embryos (Fig. 8C, asterisks, 
n=6).  Therefore, p53 was not responsible for the neural crest cell death or lacrimal gland 
aplasia in Shp2 mutants. 
 
To determine whether these early neural crest defects affect the periocular mesenchyme 
development, we crossed Wnt1-Cre with the R26R Cre reporter to follow the fate of 
neural crest cells.  Interestingly, by the time of lacrimal gland budding at E13.5, the 
periocular mesenchyme adjacent to the conjunctival epithelium was already occupied by 
the neural crest derived cells in Shp2 mutants (Fig. 8D, arrows).  Furthermore, the 
expression of Pitx2 and Foxc1, two markers of the neural crest derived periocular 
mesenchyme, were similar in control and Shp2 mutant eyes (Fig. 8E, arrows). Therefore, 
despite causing an initial delay in neural crest migration and abnormal apoptosis, Shp2 
ablation did not disrupt the occupancy of the periocular mesenchyme by the neural crest-
derived cells at the time of lacrimal gland budding.  We thus concluded that the subtle 
neural crest migration, survival and proliferation defects in Shp2 mutant were unlikely to 
account for the failure of lacrimal gland development.  
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Figure 8. Shp2 deletion did not prevent the neural crest from giving rise to the 
periocular mesenchyme. (A) In E10.5 En1-Cre;Fgf8f/f;Fgf15-/- embryos, Fgf8 was 
ablated in the midbrain- hindbrain junction, where FGF signaling response gene Etv5 was 
also down regulated, indicating a loss of FGF signaling. However, lacrimal gland budded 
at E15.5 was unaffected. Arrow and arrowhead: Fgf8 and Etv5 expressions in the 
midbrain-hindbrain junction. Asterisks: lacrimal gland bud. (B) The migrating neural 
crest marked by Sox10 expression was reduced in Wnt1- Cre;Shp2f/f and Wnt1-Cre; 
Mek1f/f;Mek2-/- mutants, but rescued in Wnt1-Cre;Shp2f/f;LSLKrasG12D embryos. Arrow and 
arrowhead: Sox10 positive neural crest cells in the periocular mesenchyme. e: eye.  (C) 
Deletion of p53 in Shp2 mutants failed to prevent aberrant apoptosis in the branchial 
arches shown by lysotracker (upper panel) and in periocular mesenchyme shown by 
cleaved caspase 3 staining (middle panel). Lacrimal gland budding was not rescued in 
Shp2/p53 double mutant (bottom panel). Arrow: lysotracker staining in the branchial 
arch. Arrowhead: apoptotic cells in the periocular mesenchyme. Asterisk: developing 
lacrimal gland bud. (D) Lineage tracing by crossing Wnt1-Cre with R26R reporter 
showed that Shp2 ablation did not prevent neural crest cells from populating the 
periocular mesenchyme after E13.5. Arrow: X-gal stained neural crest cells. (E) 
Periocular mesenchyme markers Fox1 and Pitx2 were unperturbed in Shp2 mutants. 
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3.1.5 Shp2 signaling regulates Alx1 and Alx4 expression in the periocular 
mesenchyme 
To determine the molecular basis of lacrimal gland defect in Shp2 mutants, we isolated 
E14.5 periocular mesenchyme by laser capture micro-dissection and performed RNA-seq 
analysis (Fig. 9A).  Among genes down regulated at least two folds in Shp2 mutants, the 
third and eighth most highly expressed transcription factors were Alx4 and Alx1, 
respectively (Fig. 9B). These results were confirmed by qPCR analysis of micro-
dissected tissues, which also showed significant reductions in Shp2 and Fgf10 
expressions as expected (Fig. 9C).   
 
We next focused on Alx4 and Alx1 as downstream targets of Shp2 signaling.  At E10.5 
and E11.5, Alx4 was widely expressed in the cranial mesenchyme surrounding the control 
eye, but the expression was moderately reduced in Shp2 mutants (Fig. 9D, arrows).  At 
E12.5, more pronounced reduction of Alx4 expression was evident at the temporal side of 
mutant eye, where the lacrimal gland bud would have emerged.  By E13.5, Alx4 
expression was absent in the periocular region except at the dorsal side, but recovered in 
Wnt1-Cre;Shp2f/f;LSL-KrasG12D embryos (Fig. 9D, arrowheads). Immunostaining on 
sections further confirmed that Shp2 deletion led to progressive down regulation of Alx4 
in the periocular mesenchyme, until it was entirely lost by E14.5 (Fig. 9E, arrows).  
Similarly, Alx1 in control embryos was expressed just anterior to the elongating lacrimal 
gland bud at E14.5, but this domain of Alx1 expression vanished in Shp2 mutant embryos 
(Fig. 9E, arrowheads).  These results demonstrate that the periocular expressions of both 
Alx1 and Alx4 are regulated by Shp2 signaling. 
 
3.1.6 Alx4 binds a terrestrially conserved Fgf10 genomic element to regulate its 
expression in the lacrimal gland mesenchyme 
The results above revealed a close resemblance of Alx1 and Alx4 expressions in the 
periocular mesenchyme to that of Fgf10 during embryonic development.  To evaluate this 
further, we examined their expression patterns in the neonatal lacrimal gland.  At 
postnatal day 0 (P0), Fgf10 was detectable in the mesenchymal cells, whereas the FGF- 
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Figure 9. Identification of Alx genes downstream to Shp2 in lacrimal gland 
development. (A) Schematic diagram of laser capture microscopy to isolate the 
periocular mesenchyme for RNA-seq analysis. (B) Dot plot of genes down regulated at 
least two folds in Shp2 mutant. Alx4 and Alx1 genes is marked by arrow. (C) qRT-PCR 
confirmed the deletion of Shp2 and down regulation of Fgf10, Alx1 and Alx4 in the laser 
captured periocular mesenchyme from Shp2 mutant. Student’s t test: *P<0.001, n=3. (D) 
Shp2 deletion reduced Alx4 expression in the cranial mesenchyme, especially at the 
periocular region next to the future lacrimal gland at E13.5, which was ameliorated in 
Wnt1-Cre;Shp2f/f;LSL-KrasG12D embryos. Arrow: Alx4 expression in the cranial 
mesenchyme at E10.5 and E11.5. Arrowhead: Alx4 expression in the periocular 
mesenchyme at E12.5 and E13.5. (E) In Shp2 mutants, Alx4 was progressively reduced 
in the periocular mesenchyme adjacent to the conjunctival epithelium from E12.5 to 
E13.5. By E14.5, both Alx1 and Alx4 were lost. Arrow: Alx4 immunostaining in the 
periocular mesenchyme. Arrowhead: Alx1 expression surrounding the lacrimal gland bud. 
Lacrimal gland primordia are outlined in dotted lines. 
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inducible gene Etv5 was expressed in the adjacent ducts and acini, suggesting that FGF 
signaling remained active at this stage (Fig. 10A, arrows).  As expected, both Alx1 and 
Alx4 mRNA were also found in the lacrimal gland mesenchyme.  By immunostaining, we 
further demonstrated that P3 lacrimal gland expressed Alx4 protein, which was separated 
from both epithelial marker Pax6 and myoepithelial marker SMA (Fig. 10B). Finally, to 
trace the origin of these Alx4-expressing cells in the lacrimal gland, we crossed Wnt1-Cre 
with an R26TdT (Ai14) reporter to indelibly label the neural crest-derived cells with 
tdTomato fluorescence.  By double immunostaining, we confirmed that Alx4 resided 
exclusively in the tdTomato-positive cells, demonstrating that Alx4 persisted in the 
neural crest lineage during lacrimal gland development. 
 
Based on the similarity between Alx1/4 and Fgf10 expression patterns in lacrimal gland 
development, we hypothesized that Alx1/4 were direct regulators of Fgf10 transcription. 
Since the lacrimal gland system was an adaptation of terrestrial animals to the airy 
environment, we searched Fgf10 locus for regions that were evolutionarily conserved 
from human to chicken but not to stickleback fish (Fig. 10C). We next overlaid these 
regions with DNase hypersensitive sites in 3T3 fibroblast cell line identified by the 
ENCODE project, because this cell line expressed both Alx4 and Fgf10 at high levels 
[140].  Finally, we screened these sequences using the Alx1/3/4 binding motif and 
identified a perfect match within the intron 1 of Fgf10 (Fig. 10D).  Interestingly, 
sequence alignment showed that this site was evolutionarily conserved in amphibians 
such as lizard which have the lacrimal gland, but not in Xenopus frog, which lacks the 
lacrimal gland [141]. Even among animals living both on land and in water, the lacrimal 
gland is only present in reptiles such as alligator, but not in amphibians such as frog (Fig. 
10C). To ascertain whether this sequence was a bona fide Alx binding site, we performed 
chromatin immunoprecipitation in 3T3 cells followed by qPCR using specific primers.  
Compared to IgG control, there was a ~3 fold enrichment of this putative Alx binding 
element in chromatins pulled down by Alx4 antibody (Fig. 10E).  This was further 
validated in vivo by Alx4 chromatin immunoprecipitation using the lacrimal gland 
mesenchyme isolated from neonatal pups, which resulted in a ~11 fold enrichment.  We 
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Figure 10. Alx4 binds a terrestrially conserved element in Fgf10 locus. (A) In new 
born pups, Alx1, Alx4 and Fgf10 were expressed in the lacrimal gland mesenchyme, 
whereas FGF response gene Etv5 was expressed in the epithelium. (B) Alx4 protein was 
excluded from Pax6-positive epithelial cells and SMA-positive myoepithelial cells, but it 
was expressed in the neural crest derived mesenchymal cells labeled by Wnt1-Cre 
induced tdTomato fluorescence. (C) Sequence alignment identified an Alx4 site within an 
intronic region of Fgf10, which was conserved from human to lizard, but not to Xenopus 
and fish. It resided next to DNase hypersensitivity peaks in NIH3T3 cells. (D) The Alx4 
site in Fgf10 locus matched with the Alx consensus sequence. (E) Chromatin 
immunoprecipitation showed that Alx4 directly bound the Fgf10 intronic site in both 
lacrimal gland mesenchyme and NIH3T3 cells. Student’s t test: *P<0.01, n=4; 
**P<0.001, n=3. (F) Schematic diagram of mesenchymal cell culture isolated from 
newborn pups and treatment with Alx siRNA. LGM: lacrimal gland mesenchyme. LGE: 
lacrimal gland epithelium. (G) Alx4 siRNA significantly down regulated Fgf10 
expression in lacrimal mesenchymal cells, whereas additional application of Alx1 siRNA 
did not lead to further reduction. One Way ANOVA: *P<0.01, **P<0.001, n=3. 
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next knocked down Alx1 and Alx4 using siRNAs in cultured lacrimal gland mesenchymal 
cells (Fig. 10F). Interestingly, Alx1 depletion led to a modest reduction in Fgf10 mRNA 
level, but the effect was not statistically significant (Fig. 10G).  In contrast, Alx4 
knockdown decreased Fgf10 expression by ~50%, which was not further reduced by 
combined treatment of both Alx1 and Alx4 siRNAs.  This suggested that Alx4 plays a 
more dominant role than Alx1 in regulating Fgf10 in the lacrimal gland mesenchyme. 
 
3.1.7 Alx4 is required for lacrimal gland development in mouse and human  
To determine the functional role of Alx4 in lacrimal gland development, we analyzed 
Alx4lst-J mice, which carried a frameshift mutation removing both the homeodomain and 
downstream CAR domain.  Homozygous Alx4lst-J animals displayed craniofacial defects, 
dorsal alopecia and preaxial polydactyly at birth as previously reported in Alx4 knockouts 
[142, 143]. At E14.5, Alx4lst-J homozygous embryos maintained Connexin43 and Col2a1 
expressions in the periocular mesenchyme, but the domain of Alx1 expression was more 
restricted (Fig. 11A, arrows).  Importantly, there was a drastic reduction of Fgf10 
adjacent to the lacrimal gland bud (Fig. 11A, arrows), accompanied by down regulation 
of FGF-target genes Etv4 and Etv5 in the lacrimal gland epithelium (Fig. 11A, dotted 
lines).  At E16.5, histology and immunostaining revealed a complete loss of Alx4 
expression in the periocular mesenchyme and a much shorter Pax6-expressing lacrimal 
gland bud, characterized by reduced phospho-Histone H3 (pHH3) and increasing TUNEL 
signal (Fig. 11B, dotted lines).  By P1, no lacrimal gland was detectable by Carmine 
staining in Alx4lst-J homozygous pups (Fig. 11B, black arrows). These results 
demonstrated that inactivation of Alx4 markedly disrupted Fgf10 expression and 
downstream FGF signaling, affected cell proliferation and survival, and ultimately caused 
a failure of lacrimal gland development. 
 
In human, ALX4 loss-of-function mutations underlie autosomal recessive frontonasal 
dysplasia 2 syndrome, characterized by skull defects, wide nasal bridge, notched nares, 
depressed nasal tip, hypertelorism and alopecia (OMIM 613451).  We reanalyzed one 
patient carrying a homozygous c.503delC mutation in exon 2 of ALX4 gene, which 
resulted in truncation of the homeobox (HD) and C-terminal OAR domains [144].  MRI 
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imaging in that patient revealed an absence of lacrimal glands bilaterally (Fig. 11C, 
arrows). The patient lacked tearing and experienced irritable eyes and multiple episodes 
of eye infection since birth.  This finding is consistent with the role of ALX4 in human 
lacrimal gland formation. 
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Figure 11. Alx4 inactivation led to lacrimal gland aplasia in human and mouse. (A) 
In E14.5 Alx4 knockout embryos, Connexin43 and Col2a1 expression remained in the 
periocular mesenchyme, whereas Alx1 expression domain was reduced. Fgf10, Etv4 and 
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Etv5 were significantly down regulated. Arrows: staining in the periocular mesenchyme. 
Lacrimal gland buds are outlined in dotted lines. (B) E16.5 Alx4 null mutant displayed 
only rudimentary lacrimal gland shown by histology and Pax6 staining, while Alx4 
immunostaining was lost. There were reduction of pHH3 and increase in TUNEL 
staining in the residual bud (Inserts showed magnified region of lacrimal gland buds). At 
P1, carmine staining revealed an absence of lacrimal gland in Alx4 null pups. Lacrimal 
gland buds are outlined in dotted lines. (C) MRI revealed bilateral absence of 
lacrimal gland in a patient carrying c.503delC mutation that removed the functional 
domains of ALX4. Lower panel showed enlarged region of the eye and arrows point to 
the lacrimal gland. (D) Model of neural crest Shp2 signaling in lacrimal gland 
development. Shp2 mediates FGF signaling in the developing neural crest to activate 
Ras-MAPK signaling, which is required for Alx4 expression in the periocular 
mesenchyme. By binding to an intronic element of Fgf10, Alx4 activates Fgf10 
expression to induce lacrimal gland budding. 
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3.2 Etv/Pea3 transcription factors are required for establishing lacrimal gland cell 
fate, duct elongation and branching morphogenesis 
3.2.1 Pea3 transcription factors are critical for lacrimal gland development 
Lacrimal gland development begins with the thickening of the conjunctival epithelium at 
E13.5 and forms a bud invaginating into the surrounding periocular mesenchyme by 
E14.5. This process is triggered by the mesenchymal Fgf10 which activates Fgf signaling 
in the epithelium. Pea3 family of Ets transcription factors: Pea3/Etv4, Erm/Etv5, 
Er81/Etv1, which are early response genes downstream of Fgf signaling are upregulated 
in the lacrimal gland epithelial bud (Fig. 12C, E and G, dotted lines). In order to study the 
function of these transcription factors, we conditionally deleted two members of the Pea3 
family of transcription factors, Erm and Er81 in the Pea3 KO background using Le-Cre 
transgenic mouse line, where Cre-recombinase is linked to an IRES-GFP reporter [43]. 
Deletion of Pea3 genes was confirmed by in situ hybridization of Etv4, Etv5 and Er81 
(Fig. 12D, F and H, dotted lines). In Le-cre, Pea3-/-, Ermfl/fl, Er81fl/fl (hereafter, referred to 
as Pea3 TKO), we found that the lacrimal gland bud is smaller in size compared to 
control at E14.5 as shown by the expression of lacrimal gland progenitor cell marker, 
Pax6 and the epithelial marker, E-cadh (Fig. 12A, B, arrows). Analysis at post-natal 
stages P1-3 showed that duct elongation and branching are severely affected as evident 
by malformed gland marked by GFP expression in Pea3 TKO (Fig. 12I-L). This 
phenotype in Pea3 TKO is more severe compared to the mice carrying one normal copy 
of Pea3 gene, indicating that Pea3 is not redundant during lacrimal gland development. 
These results indicate that Pea3 transcription factors are important for lacrimal gland 
development.  
 
3.2.2 Pea3 transcription factors mediate Fgf signaling during lacrimal gland 
development 
In order to decipher the gene regulatory network of Pea3 transcription factors, mouse 
lacrimal gland epithelial tissue from control (Le-Cre) and mutant (Pea3 TKO) mice were 
micro-dissected using laser capture microscopy and subjected to RNA-seq at E14.5 stage 
(n=3 per condition, Fig. 13A).  Unbiased clustering analysis of the normalized data 
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Figure 12. Pea3 transcription factors are important for lacrimal gland development. 
(A-H) Le-Cre mediated deletion of Pea3 genes resulted in smaller lacrimal gland buds 
(A-B, arrows) and abrogation of expression of Pea3 transcription factors Erm, Er81 and 
Pea3 at E14.5-15.5 stage (C-H, dotted lines). (I-L) Analysis at post-natal stage, P1, 
demonstrated that complete lack of Pea3 transcription factors led to more severe 
phenotype as shown by GFP (I and K, arrows) in comparison to embryos which have one 
wild-type copy of Pea3 still present (J and K, arrows).  
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revealed that control and mutant samples were clustered in two separate groups and data 
from individual samples within each group were highly correlated (r= 0.8, Fig. 13B). 
These results indicated the robustness of our data. To analyze which signaling pathways 
or processes are downregulated in Pea3 TKO mutants, KEGG pathway analysis using 
DAVID was performed, which showed that several genes involved in PI3-Akt, Ras 
pathways and ECM receptor interaction processes are significantly downregulated (Fig. 
13C).  
 
These data were further validated by gene set enrichment analysis (GSEA) using a 
reference database previously published for lacrimal gland epithelium in Fgfr2 
conditional knockout mice generated in a similar fashion as described above at E13.5 
stage in mouse [33]. GSEA is a computational tool which evaluates whether a given set 
of genes shows a statistical significant difference between two biological states 
(phenotypes).  The results of this analysis revealed that significantly downregulated genes 
in Pea3 TKO mutants were also downregulated in Fgfr2 conditional mutants, with 
normalized enrichment score (NES) as -6.8 and p <0.01(Fig. 13D). NES is a statistic to 
compare the enrichment results and takes into account the differences in the size of the 
genesets as well as the different correlations between the genesets and expression 
datasets. Similarly, significantly upregulated genes in Pea3 TKO mouse mutants are 
downregulated in the Fgfr2 dataset (NES = -4.4, p <0.01) (Fig. 13E). One of the reasons 
could be that since Fgfr2 is at the very top of the signaling cascade, its ablation can 
suppress the upregulation of compensatory genes in Pea3 mutants. Taken together, these 
results are consistent with the earlier findings that Pea3 family of genes are downstream 
of the Fgf signaling cascade.  
 
3.2.3 Pea3 genes are required for establishing the lacrimal gland fate 
From RNA-seq data, another interesting observation was the upregulation of keratins- 
Keratin 5, 14, 17 in Pea3 TKO mutant mice, confirmed by immunostaining against Krt14  
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Figure 13. Bioinformatics analysis indicates Pea3 transcription factors are 
downstream of Fgf signaling during lacrimal gland development. (A) Schematic of 
RNA-seq following Laser capture microdissection of lacrimal gland bud in control and 
Pea3 TKO mutants. Lacrimal gland images of before and after the dissection process are 
shown. (B) Clustergram analysis of top 200 differentially expressed genes in RNA-seq 
data from 6 samples (Control, n=3, Mutant, n=3), showed that control and mutant 
samples form two separate clusters, indicating robustness of our samples (r = 0.8). (C) 
KEGG pathway analysis of downregulated genes in Pea3 mutant using DAVID indicated 
several key pathways such as PI3-AKT, Receptor interaction, MAPK, 
Glycosaminoglycan synthesis pathways were significantly downregulated. (D-E) Gene 
set enrichment analysis of downregulated genes in Pea3 mutants indicated that these 
genes were significantly enriched in reference database curated from published RNA-seq 
data from the Fgfr2-deleted conjunctival epithelium at the time of lacrimal gland 
development (D, p<0.01). Similar analysis with upregulated geneset also shows 
significant enrichment (E, p<0.01). 
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(Fig. 14A, B, arrows). These keratin genes are typically expressed in skin cells, more 
specifically in the epidermis, although the lacrimal gland progenitor cell marker Pax6 
was still present in Pea3 TKO mutants (Fig. 12A, B). This led us to hypothesize that there 
was shift in cell identity from the lacrimal gland fate to the epidermal skin-like fate. To 
test this idea, we performed GSEA of differentially upregulated genes in Pea3 TKO 
mutants with reference to published gene expression datasets of different cell types 
present in mouse embryonic skin at E14.5 stage [145]. Upon analysis, we found that there 
is significant enrichment of upregulated genes in the epidermis and placodal datasets 
(epidermis- p< 0.001; placodal cells- p<0.001) (Fig. 14C, D). Notably, similar analysis 
with other skin cell types such as dermis, schwann cells, melanoctyes, and fibroblasts did 
not show any enrichment (Fig. 14E-I). Supporting this observation, we also performed 
principal component analysis (PCA) of our data with the published gene expression 
datasets of different cell types within the embryonic skin. PCA reduces the 
dimensionality of the data and linearly maps the data into lower-dimensional space in 
such a way that it captures the maximum variation in the data. This analysis revealed that 
the gene expression profile of Pea3 TKO mutant, but not that of the control lacrimal 
gland, clusters with gene expression pattern of epidermal cells along first and second 
principal component axes as well as first and third principal component axes (Fig. 14J, 
K). These data demonstrate that Pea3 transcription factors are required for maintaining 
the lacrimal gland cell fate during its development, absence of which pushes the lacrimal 
gland progenitor cells into the skin-like cell fate.  
 
3.2.4 Pea3 genes control expression of Six1 and Six2 required for lacrimal gland 
development 
To understand the mechanism of this change in the cell fate, we sought to determine the 
most differentially regulated genes in our dataset. For this analysis, gene expression 
values, Log2 (fold change), was plotted on x-axis against the corresponding Log2 (p-
value) on y-axis (Fig. 15A). Several known Fgf-responsive genes such as Spry4, Dusp6, 
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Figure 14.  Pea3 genes are required for establishing the lacrimal gland cell fate. 
(A-B) Keratin 14, an epidermal skin marker, is upregulated in the lacrimal gland bud of 
Pea3 mutants (B dotted line, arrow). (C-D) GSEA analysis of differentially upregulated 
genes in Pea3 mutants shows a significant enrichment in the epidermal skin reference 
database. (E-I) There was no enrichment in the reference gene expression datasets from 
other cell types present within the skin. (J-K) Principal component analysis of RNA-seq 
data from different skin cell types as well as from lacrimal gland tissues from control and 
Pea3 mutants. Analysis indicated that mutant lacrimal gland is more closely related to the 
epidermal skin compared to the control lacrimal gland along first and second as well as 
first and third principal axes. 
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ECM encoding genes- Col2a1, Col9a1, were down-regulated in Pea3 mutants. 
Interestingly, among Sox genes, which were reported to be downstream of Fgf signaling 
during lacrimal gland development, Sox10 was dramatically downregulated whereas 
Sox9 showed no significant change. This is consistent with previous finding that ablation 
of Sox9 downregulated phospho-Erk and Erm in the epithelium, suggesting that Sox9 is 
upstream of Pea3 genes [33]. Of note, transcription factors Six1 and Six2 also emerged as 
promising candidate genes. Six1 mutant has been previously shown to have defects in 
duct elongation and branching during lacrimal gland development in mouse [45]. 
Moreover, Six2 has been shown to be downstream of Six1 in human embryonic stem 
cell-derived lacrimal gland cells [146]. 
 
We validated these findings by performing in situ hybridization and immunostaining for 
most of these genes. Indeed, in situ hybridization revealed that the expression of Six1 and 
Six2 were significantly downregulated in Pea3 mutants (Fig. 15B-E, dotted lines). 
Similarly, the expression of Sox10 and Dusp6 were diminished in the mutants, consistent 
with the RNA-seq data. Immunostaining for Col2a1 revealed that its expression was 
downregulated in the epithelial basement membrane (Fig. 15F-K, white dotted lines, 
arrows). To show that the expression of Six1 and Six2 are driven by Fgf-signaling, we 
performed similar in situ hybridization of Six1 and Six2 in mice with epithelial deletion of 
Fgfr2. Our results demonstrated that expression of Six1/2 and Erm were completely 
abolished in Le-Cre, Fgfr2fl/fl embryos at the E14.5 stage (Fig. 15L-S, dotted lines, 
arrows) in the conjunctival tissue which still retains Pax6 expression, suggesting that 
Six1 and Six2 are downstream targets of Pea3-mediated Fgf signaling in the epithelium. 
We further explored the genetic requirement of Six genes during lacrimal gland 
development. Interestingly, unlike Six1 KO mice, Six2 KO mice do not have lacrimal 
gland defect (data not shown) suggesting that Six1 might be compensating for Six2 
during lacrimal gland development. 
 
Since Pea3 are direct responsive genes of Erk signaling, we proposed that these Fgf-
responsive genes could be direct targets of Pea3 transcription factors. To analyze this, we  
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Figure 15. Six1 and Six2 are downstream targets of Fgf signaling mediated by Pea3 
transcription factors. Volcano plot demonstrating the relative distribution of 
differentially expressed genes, with respect to fold change and statistical significance, red 
dots highlighting Six family genes, Six1, Six2, and previously published downstream 
targets of Fgf signaling. (A-J) In situ hybridization against Six1 and Six2 show that 
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expression of these Six genes are downregulated in Pea3 TKO (A-D, dotted lines). (E-J) 
Expression of Sox10, Col2a1 and Dusp6 reported to be downstream targets of Fgf 
signaling were downregulated in Pea3 TKO mutants (dotted lines, arrows). (K-R) 
Expression of Six1 and Six2 were also downregulated in the Le-Cre, Fgfr2fl/fl mutant 
lacrimal gland epithelium (O-R, dotted lines) which retained progenitor differentiation 
marker Pax6 and epithelial marker E-cadherin in mutants (K, L, dotted lines). As 
expected, expression of Erm was also abolished in Fgfr2 conditional knockout epithelium 
(M-N, dotted lines). 
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used published ChIP–seq data for targets of Pea3 and Er81 in cancer cell lines and used 
intersection-of-list approach to find the common targets among significantly 
downregulated genes in Pea3 TKO mutants [147, 148]. We found that, among direct 
targets of Pea3, 61 genes are upregulated in Pea3 TKO, whereas 57 genes are 
downregulated, including Six1, Col2a1, Dusp6 and Etv4 itself. Similar analysis with 
direct targets of Er81 transcription factor revealed that 31 gene targets are upregulated in 
Pea3 TKO and 39 gene targets are downregulated, including Six2 and Col8a2 (Fig. 16A, 
B). Since this information is based on the human cell line data, we further performed 
Transfac analysis under stringent criteria and identified the binding sites of Pea3, Erm 
and Er81 in the promoter regions (5kb upstream) of these genes (Fig. 16C) in mouse 
genome. Taken together, these data demonstrate for the first time that Six1 and Six2 are 
downstream of Pea3 signaling important for lacrimal gland development and potentially 
regulate the lacrimal gland cell fate. 
 
3.2.5 Pea3 transcription factors suppress Notch signaling during lacrimal gland 
development 
With the observed upregulation of epidermal markers and downregulation of Six1 and 
Six2, we hypothesized that Six genes are important for regulating the lacrimal gland cell 
identity. To test this hypothesis, we analyzed the genes and signaling pathways which 
were upregulated in Pea3 mutants. DAVID-KEGG pathway analysis of the RNA-seq 
data revealed that Hippo, Wnt and Notch signaling pathways were upregulated in Pea3 
TKO mutant glands (Fig. 17A). To validate these findings, we performed GSEA to find 
enrichment of genesets from these upregulated signaling pathways in our dataset. Our 
analysis indicated that Notch target genes were significantly enriched in our dataset but 
not those from the Hippo or Wnt signaling pathways (NES = 2.56, p<0.01, Fig. 17B-D). 
Plotting differential gene expression values, Log2 (fold change) vs corresponding Log2(p-
value) on y-axis revealed that several genes associated with Notch pathway were 
upregulated in Pea3 TKO mutants as highlighted in the volcano plot (Fig. 17E). We 
confirmed these results by immunostaining and observed an increased expression of Jag1 
and Notch1-ICD in Pea3 TKO (Fig. 17F-I, dotted lines, arrows). 
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Figure 16. Six1 and Six2 can potentially be direct targets of Pea3 transcription 
factors.  (A-B) Intersection-of-list analysis was performed with published Pea3 and Er81 
ChIP on tumor cell lines and differentially regulated genesets in Pea3 mutants, indicating 
that Six1 and Six2 can be direct targets of Pea3 genes during lacrimal gland development. 
(C) Transfac analysis of genomic region 5 kb upstream of murine Six1, Six2, Col2a1 and 
Dusp6 genes showed putative binding sites of Pea3 transcription factors.  
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Based on these results, we concluded that for acquiring the lacrimal gland cell fate, Notch 
signaling must be downregulated in the lacrimal gland epithelium, suggesting that it was 
under negative regulation by Pea3-mediated Fgf signaling. To confirm these findings in 
vivo, we overexpressed Notch1-ICD (NICD) allele in the lacrimal gland using Le-Cre 
and found that lacrimal gland formation was completely disrupted (n=10, Fig. 18A-C). 
To further investigate whether Six1 and Six2 gene expression also depend on suppression 
of Notch signaling, we performed in situ hybridization for Six1 and Six2 to find that the 
expression of these genes were indeed ablated in Le Cre, Rosa-NICD embryos, while the 
expression of lacrimal gland progenitor cell marker Pax6 was retained (Fig. 18D-G, P-Q, 
n=4). Furthermore, expression of target genes downstream of Fgf signaling such as 
Sox10, Erm, Pea3 and Dusp6 were also downregulated in these mutants (Fig. 18H-O, 
n=4), consistent with the loss of lacrimal gland cell fate. Interestingly, we found that Jag1 
was upregulated in these mutants, suggestive of the lateral activation of Notch signaling 
acting as a positive feedback loop to increase Jag1 expression (Fig. 18R-S, dotted lines). 
Taken together, these results show that Pea3 is responsible for suppression of Notch 
signaling in maintaining the lacrimal gland cell fate (Fig. 18T). 
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Figure 17. Fgf signaling mediated by Pea3 genes suppresses notch signaling during 
lacrimal gland development. A. KEGG pathway analysis of upregulated genes indicated 
that several signaling pathways such as Notch, Hippo and Wnt were upregulated. (B) 
Gene set enrichment analysis of published Notch signaling geneset with reference to Pea3 
differential gene expression dataset indicated an enrichment of Notch signaling genes but 
not Hippo and Wnt signaling genes (C-D). (E) Log2(Fold change) vs Log2(p-value) 
indicated that several Notch pathway genes were upregulated, highlighted by red dots. (F-
I) Antibody staining against Jag1 and N1-ICD showed an ectopic increase in the 
expression of these Notch signaling activators in Pea3 mutant lacrimal glands (G, I, 
dotted lines, arrows). 
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Figure 18. Ectopic activation of Notch signaling in the lacrimal gland epithelium 
aborts gland development. (A-C) Analysis at pups at P1 stage showed that mice with 
overexpression of N1-ICD in the lacrimal gland epithelium failed to form lacrimal gland 
(B, arrow). (D-O) Analysis of embryos at the E14.5 stage using in situ hybridization 
showed that the expression of Six genes was abolished (D-G, dotted lines), concomitant 
with the loss of expression of other Fgf signaling target genes- Erm, Pea3, Dusp6 and 
Sox10 (H-O, dotted lines). (P-S) Expression of N1-ICD maintained lacrimal gland 
progenitor cell population as shown by Pax6 and E-cadherin expression (P, Q, dotted) 
and it also resulted in activation of auto-stimulatory loop via upregulation of Jag1 
expression (R, S, dotted lines). (T) Graphical summary of the gene regulatory network 
summarizing the signaling mechanisms associated with Pea3 transcriptional network 
during lacrimal gland epithelial development.  
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4 Discussion 
 
Lacrimal gland development is a highly-regulated process driven by extrinsic and 
intrinsic signaling interactions, often involving multiple tissue types which orchestrate to 
form the functional structure. Lacrimal gland formation is based on the cross-talk 
between the surrounding neural crest-derived mesenchyme and the conjunctival 
epithelium tissue. During organogenesis of the lacrimal gland, multiple signaling 
pathways, most notably, Fgf, BMP, Notch and Wnt are involved in establishing different 
cell fates. These signaling interactions often strive for maintaining just the right level of 
signaling activity of the respective pathways by either supporting or antagonizing each 
other in tissue-specific manners.  
 
Our current knowledge of the lacrimal gland is largely restricted to epithelium rather than 
in the mesenchyme, in part due to the fact that over 90% of the mature lacrimal gland is 
of the epithelial origin. Mesenchymal condensation is one of the earliest events in 
lacrimal gland development, but its mechanism and functional significance remain poorly 
understood. The focus of this thesis study is two folds- one is to understand the 
development of the lacrimal gland mesenchyme, more specifically, the signaling 
mechanisms which are important for regulating Fgf10 production. The other is to 
understand the role of direct downstream targets of sequential Fgf signaling pathway 
triggered within the epithelium during the development of lacrimal gland. 
 
4.1 Understanding the development of lacrimal gland mesenchyme 
In this study, we show that FGF signaling in the neural crest is required for Fgf10 
production within the periocular mesenchyme, which triggers a second round of FGF 
signaling in the conjunctival epithelium to form the lacrimal gland (Fig. 7D). This is 
mediated by Frs2α and Shp2, which activates Ras-MAPK pathway to control the 
survival, migration and differentiation of the cranial neural crest. The downstream 
effector of Shp2 signaling in the periocular mesenchyme is homeodomain transcription 
factor Alx4, which acts as a relay to transmit earlier FGF signaling in the neural crest to 
induce Fgf10 signaling in the lacrimal gland. Our results highlight the role of Alx4 in 
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inducing reiterative FGF signaling in neural crest development and reveal the etiology of 
lacrimal insufficiency in ALX4-/- patients. 
 
The source of the FGF signaling in the neural crest for lacrimal gland development is an 
intriguing question.  It is unlikely autocrine signaling of Fgf10, because deletion of Fgfr2, 
the cognate receptor for Fgf10, in the neural crest only produced minor defects in 
lacrimal gland development (Fig. 2). We have tested Fgf9, which is expressed in the 
periocular mesenchyme, but lacrimal gland development was unaffected in Fgf9 
knockout animals (data not shown).  Fgf8 is known to play important roles in neural crest 
development [126, 127, 136, 137, 139], but deletion of Fgf8 in the midbrain-hindbrain 
junction, branchial arches or the forebrain failed to disrupt lacrimal gland development 
(data not shown). Considering the complexity of FGF family, additional work is needed 
to identify the relevant FGF ligands in the neural crest. 
 
RASopathies represent a spectrum of congenital abnormalities caused by aberrant Ras-
MAPK signaling, but the relevant RTK signaling pathway mediated by Ras in normal 
development is not always clear [149, 150]. Using mouse genetics, we showed that 
defective FGF signaling, but not PDGF signaling, in the neural crest reproduced the Shp2 
deletion phenotype in the lacrimal gland, thereby positioning FGF receptors as the 
primary regulators of Shp2 in neural crest and lacrimal gland development.  Contrary to a 
previous study in zebrafish, we did not find Shp2 acts upstream to p53 to suppress neural 
crest cell apoptosis [134]. This discrepancy could be due to difference in species or the 
experimental approaches as we used genetic knockout whereas the zebrafish study used 
morpholinos knockdown. Instead, our genetic evidence demonstrates a fundamental role 
for the Shp2-Ras-Mek-Erk signaling cascade in neural crest survival and development. 
MAPK is known to phosphorylate and induce the ETS domain transcription factors, 
which act as downstream effectors in gene regulation. In particular, the expressions of 
Pea3 family genes Etv1/4/5 correlate closely with FGF signaling activities during 
embryonic development [25]. However, deletion of all three Pea3 family genes in the 
neural crest failed to produce any craniofacial or lacrimal gland defects, but 
overexpression of a dominant-negative Etv4 indeed stunted lacrimal gland growth. This 
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suggests that other members of the ETS domain transcription factors, which recognize 
similar binding sites as Etv1/4/5, can play redundant roles in transmitting FGF-MAPK 
signaling in the neural crest development. 
 
With the prior understanding of the role of Fgf signaling in proliferation and 
differentiation of gland epithelium, our study demonstrated that Fgf signaling also plays a 
role in differentiation of neural crest-derived mesenchyme to produce Fgf10. However, 
our current study does not demonstrate the spatiotemporal requirement of Fgf signaling.  
Based on the expression of Pea3, Erm, Er81 and previously reported phospho-ERK 
staining data [25], it appears that neural crest cells may not experience active Erk 
signaling at that time of expressing Fgf10. Activation of Erk signaling is very dynamic 
during the embryonic development. Further development of mouse models will be 
necessary to precisely determine the timing and site of Fgf signaling resulting in 
differentiation of neural crest cells to produce Fgf10 during lacrimal gland development. 
With the Wnt-1 Cre specific deletion, one could argue that Fgf signaling might be 
required in the pre-migratory phase as the expression of Wnt-1 Cre discontinues at the 
onset of migration. However, Sox10-Cre driven deletion of Shp2 in migrating neural 
crest cells suggests that the window for Fgf signaling requirement must be between the 
migratory and differentiation phases (E10.5- E12.5). Ongoing studies is taking advantage 
of Pdgfrα–CreEr mouse line, as Pdgfrα continues to be expressed by neural crest cells 
even after reaching their destination to produce Fgf10. Hence, deletion of Fgfr1/2 at 
different time-points by activating Pdgfrα-CreEr with tamoxifen injections to pregnant 
females, followed by determining the lacrimal gland phenotype in embryos, can help 
identify the specific time-point when Fgf signaling is required.  
 
Our study demonstrates that Alx genes are the ultimate downstream effectors of Shp2 
signaling in the periocular mesenchyme. Alx4 shares sequence and structural homologies 
of paired-type homeodomain and C-terminal aristaless domain with two other 
transcription factors, Alx1 and Alx3. These proteins are present within the craniofacial 
mesenchyme and limb bud, showing overlapping expression patterns [112]. Members of 
this family of transcription factors also display functional redundancies as shown by 
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genetic interactions in specific tissues. Alx3 knockout mice were morphologically normal, 
but Alx3/4 double mutants displayed more severe defects in the neural crest-derived 
craniofacial structures than Alx4 knockout alone [112]. Alx1 null mice showed 
craniofacial defects distinct from Alx4 mutants and combined deletion of both genes led 
to developmental abnormalities not found in either of the single mutants, indicating that 
Alx1 and Alx4 have both unique and redundant roles [143]. The lacrimal gland 
mesenchyme expresses Alx1 and Alx4, but not Alx3. Although we did not observe a 
synergistic effect of Alx1 and Alx4 in our in vitro experiment, it remains possible that 
Alx4/Alx1 double knockout mice will present more severe lacrimal gland defects as the 
neural crest Shp2 mutant.   
 
The main and accessory lacrimal glands secrete the aqueous component of the tear film, 
and play an important role in maintaining the health and transparency of the ocular 
surface.  Because the tear is only necessary for land animals whose eyes are constantly 
exposed to the air, but not for animals living in an aquatic environment, the lacrimal 
gland emerges relatively late in tetrapods during vertebrate evolution.  In this study, we 
show that the Alx4 binding site in the Fgf10 locus lies within a region conserved from 
human to alligator, but not to frog and fish.  This suggests that, although both Alx4 and 
Fgf10 arise in more primitive organisms, these two genes are probably not functionally 
linked until the emergence of the lacrimal gland in reptiles.  Considering that Fgf10 lies 
at the top of the genetic cascade for inducing branching morphogenesis in many 
glandular organs, this represents an example of evolution that coopts an existing genetic 
circuitry to develop new organs to adapt to new environment.  By showing that the Alx4-
Fgf10 axis is conserved from mouse to human, our study contributes to the understanding 
of the role of Alx4 in human neural crest and lacrimal development and points the 
direction to generate the lacrimal gland from pluripotent stem cells. 
 
Our data suggests that Alx4 is downstream of Shp2-mediated Fgf signaling as a 
potentiating factor for the production of Fgf10. Again, considering Erm/Pea3/Er81 as Fgf 
signaling readout, it is still unclear at what stage during development Alx4 is regulated by 
Fgf signaling. Previous studies have shown that Alx4 is genetically linked to activators of 
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BMP pathway during limb development  [151] and Foxc1 mediates BMP activation of 
Alx4 during calvarial bone development [152]. Another study showed that during 
pubescent mammary gland development, Alx4 regulates the expression of MMP2 and 
MMP9 in the stroma [153]. During skull vault differentiation, Alx4 and Msx2 genetically 
interact to regulate the expression of Fgfr1/2 and Spp1, an ossification marker [154]. 
Alx4 and Lef1 showed physical interactions in vitro and showed genetic interaction 
during vasculogenesis [155, 156]. However, we did not detect expression of Lef-1 in the 
lacrimal gland mesenchyme. In our study, the rescue of Alx4 expression by expressing 
constitutively active Kras in Shp2-deleted mice, suggests that Alx4 is regulated by Shp2-
Ras in the neural crest-derived lacrimal gland mesenchyme, which in turn regulates 
Fgf10 transcription. Alx4 is relatively understudied transcription factor in terms of its 
direct binding sites and regulation of the target genes. Through bioinformatics and ChIP 
analyses, we confirmed that a site within the intron 1 of Fgf10 is regulated by Alx4. 
Functional assays either by cloning that site upstream of a luciferase reporter, followed 
by transfection in the mesenchyme cells or by generating a mouse mutant through 
CRISPR-Cas9 to delete the reported site, will further confirm Ax4-Fgf10 interaction in 
vivo.  
 
Alx4, a homeodomain transcription factor, has been found to be expressed in 
mesenchymal regions in a number of developing tissues in wide range of species. 
Interestingly, Alx4 has also been reported to be acting as either tumor promoters or 
suppressors [157-159]. The epigenetic methylation pattern in Alx4 has been suggested as 
a potential blood-based biomarker for colon and GI cancers [160, 161]. The revelation 
that a human patient harboring an autosomal recessive mutation in ALX4 has lacrimal 
gland defects informs us the cause of the dry eye symptoms [144]. This would help 
clinicians to better manage the symptoms of such patients and adopt appropriate 
treatment strategies. Our findings not only contribute towards understanding the Alx4 
associated signaling pathways in normal development but may also shed a light on 
tumorigenesis pathways. 
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4.2 Understanding the development of lacrimal gland epithelium 
In this study, we showed that mediated by Pea3 family of transcription factors are not 
only critical for lacrimal gland duct elongation and branching but also for establishing the 
identity of the lacrimal gland epithelium derived from the progenitor conjunctival 
epithelium. High-throughput gene expression analysis revealed that, apart from 
regulating previously reported Fgf-responsive genes, Pea3 genes also regulate the 
expression of Six1 and Six2 during lacrimal gland development in mice. Our data also 
indicated that Pea3 transcription factors are important for establishing the tissue identity 
of the lacrimal gland cell by preventing the cell fate switch to the epidermal skin-like 
cells. Further analysis revealed that lack of Pea3 genes resulted in activation of Notch 
signaling. Constitutive activation of Notch signaling in the conjunctiva abrogated 
lacrimal gland development concomitant with the loss of Six1/Six2 expression. These 
results indicated that Pea3 genes suppresses Notch signaling to promote the expression of 
Six1/Six2 in order to determine the lacrimal gland cell fate and subsequent gland 
development.  
 
Transcription factor Six1 has been previously shown to regulate lacrimal gland 
development in humans as well as in mice, however, genetic regulation of this 
transcription factor was not understood. In humans, heterozygous missense mutation in 
SIX1 gene is autosomal dominant and causes lacrimal gland stenosis whereas Six1 
knockout mouse embryos have small lacrimal glands exhibiting duct elongation and 
branching defects [45]. Six1 is widely expressed in the head mesenchyme in the early 
stages of development, in addition to its expression in the ducts and acini of the lacrimal 
gland. Hence, Six1 transcription factor could be important for regulating the lacrimal 
gland mesenchyme as well as the epithelia. It is interesting that lacrimal gland formation 
is not disrupted completely in these Six1 KO mice which could be attributed to the 
presence of Six2 compensating for the loss of Six1.  Six2 has been shown to be 
downstream of Six1, which contraindicates the compensation mechanism [146, 162].  
However, it is also possible that Six2 is regulated via a separate mechanism independent 
of Six1. In addition, we found that Six2 KO does not have lacrimal gland phenotype, 
indicating that perhaps Six1 is compensating for Six2. Piecing these information together, 
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it is likely that Six1 and Six2 interact genetically and Six1/Six2 double knockout mice 
would exhibit more severe lacrimal gland phenotype. To address this question, ongoing 
studies involve carrying out lacrimal gland organ culture in the presence of Six1 siRNA 
alone, Six2 siRNA alone and Six2 siRNA in the presence of hypomorphic Six1 siRNA 
conditions to understand the genetic interactions between Six1 and Six2. Preliminary 
results suggest that Six1 is more critical gene with Six2 genetically redundant and these 
genes interact genetically in ex-vivo organ cultures but these results need further 
confirmation.  
 
There has been very limited understanding in terms of signaling mechanisms regulating 
Six1/Six2 expression. Apart from lacrimal gland defects, Six1 deficiency causes defects 
in other organs. Development of some of these organs such as the inner ear and kidney 
are based on the epithelial-mesenchymal interaction. Six1 has been further shown to have 
synergistic genetic interactions with Eya1 in mice, consistent with both genes as causes 
of human BOR/BO syndromes [162, 163, OMIM 608389, OMIM, 113650, 164]. Similar 
genetic interaction experiments in mice showed that Six1 acts upstream of Jag1 in Notch 
signaling pathway during inner ear development [165]. Systems-level analysis of inner 
ear development showed that Pea3 negatively regulates pre-placodal genes Six1 and Eya2 
[166]. The role of Six2 has also been implicated in kidney development in zebrafish, 
mice and humans [167-169].  During kidney development, both Six1and Six2 are 
expressed in cap mesenchymal tissue and are required for the proper ureteric budding and 
branching process [162, 170, 171], whereas Pea and Erm transcription factors are 
expressed in both the ureteric bud as well as the metanephric mesenchyme, however, 
only the epithelial requirement of Pea3 genes was demonstrated during embryonic 
kidney development [76]. Given the understanding of the specific roles of Six1/Six2 
genes during development of different organs, the signaling mechanisms and 
transcription factors regulating Six gene expressions are not clear. Our data revealed that 
Six1/2 are not expressed in the lacrimal gland mesenchyme but are highly expressed in 
lacrimal gland epithelium. The expression of Six1/Six2 is potentially regulated directly by 
Pea3 transcription factors downstream of Fgf signaling pathway in the lacrimal gland 
epithelium. In contrast to the findings within the inner ear tissue, Pea3 genes negatively 
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regulate Jag1 and prevent the Notch activity in the growing lacrimal gland epithelial bud. 
As a proof of principal, we showed that ectopic activation of Notch signaling resulted in 
upregulation of Jag1 with concomitant downregulation of Six genes. These findings 
highlight the context-dependent prevalence of gene regulatory networks.  
 
We have shown that Pea3 transcription factors downregulate Notch signaling in the 
lacrimal gland epithelium, however, the mechanism of this process remains to be 
understood. Analysis of our RNA-seq data for the modulators of Notch signaling showed 
that Lfng was the only Fringe family gene expressed in the control lacrimal glands, and it 
is significantly downregulated in Pea3 mutants.  Lfng is the glycosyltransferase which 
can glycosylate O-linked fucose residues on the extracellular domain of Notch receptor 
and hence, modulate the ligand binding [172]. Lfng has been shown to modulate Notch 1 
signaling by potentiating the Dll-mediated and inhibiting Jag1-mediated signaling [173-
175]. During sensory hair cell development in the inner ear, Lfng co-expresses with Jag1 
and partially rescues the phenotype when mutated in Jag2 knockout mice [176, 177]. 
During lacrimal gland development, one possibility is that activation of Pea3 
transcription factors turns on the expression of Lfng, which prevents Jag1-mediated 
Notch signaling. In the absence of Pea3 factors, down-regulation of Lfng levels results in 
Notch activation which is further potentiated by increasing Jag1 expression. Further 
investigation is required to establish the molecular link between the Pea3 genes and 
Notch signaling i.e. how is Notch signaling suppressed upon activation of Pea3 genes in 
the lacrimal gland bud.  
 
Our data has shown that the lacrimal gland cell fate is established by Pea3 transcription 
factors, absence of which result in the cell fate switch in the epithelium marked by the 
ectopic expression of epidermal skin markers. We have validated this cell fate conversion 
by bioinformatics approaches as well as immunostaining of Keratin 14. Interestingly, 
Keratin 14 is highly expressed in skin but only a few cells in the conjunctiva express 
Keratin 14. Specific upregulation of this keratin in the lacrimal gland bud of the mutants 
suggests that the lacrimal gland acquires the skin-cell fate as opposed to the conjunctival 
cell fate. This model was consistent with preliminary finding with respect to the 
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expression of Klf5 and Keratin 15, which are expressed by both the conjunctiva and skin 
cells and do not show any differential expression in the lacrimal gland bud of the 
mutants. Ongoing research include further validation of our findings with 
immunostaining of other epidermal skin biomarkers such as plakin family of genes- 
Envoplakin and Periplakin which form the component of desmosomes and the epidermal 
cornified epithelium, and Keratins 17-19.  This novel phenomenon of cell-fate switch in 
the lacrimal gland demonstrates the role of Pea3 genes in establishing the identity of 
lacrimal gland cells by not only regulating the expression of lacrimal gland specific genes 
and but also suppressing Notch signaling as well as preventing the expression of genes 
driving the skin cell fate.  
 
Since lacrimal gland induction was not aborted in Pea3 mutants similar to Fgfr2 
knockout phenotype, one can argue that there are other responsive genes apart from Pea3 
downstream of Fgf signaling. Pea3 transcription factors belong to the large family of Ets 
transcription factors. It is a possibility that other Ets genes are also relaying the Fgf10 
signal. To address this, we expressed dominant negative-Etv4 in lacrimal gland 
epithelium, but did not find any lacrimal gland defect (data not shown). This suggests that 
even the reduced amounts of Ets transcriptional activity is enough for relaying the Fgf10 
signaling activity. Sox9 is another transcription factor downstream of Fgf signaling 
pathway which remains unchanged in Pea3 mutants. Sox9 was reported to influence the 
availability and receptor binding of Fgf10, by regulating heparan sulphate synthesis in a 
positive feedback loop. Genetic deletion of Sox9 in the lacrimal gland epithelium resulted 
in a complete abortion of lacrimal gland development and down regulation of Erm and 
phospho-Erk in the epithelium, which means that Sox9 is activated in a parallel pathway 
mechanism upstream to Pea3 genes. Unlike Sox9, other transcription factors such as 
Sox10, Six1, Six2 are all downregulated in Pea3 mutants. Our data is consistent with the 
previously published results of Sox gene regulation and uncovers the previously 
uncharacterized gene regulatory network involving Six genes and Notch signaling 
pathway during the development of the lacrimal gland (Fig. 14T). This knowledge will 
help better understanding and advancement of stem cell therapeutic approaches for the 
treatment of lacrimal gland-associated dry eye diseases.  
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4.3 Current status of therapeutic advances in regenerative medicine and future 
research  
Aqueous-deficient dry eye disease is a major health challenge that lacks effective 
treatment. Although lacrimal gland transplantation is potentially feasible, it is plagued by 
immunological complications and donor shortage. To overcome donor shortage, 
xenogeneic porcine organ transplantation has been proposed, however, it has not been 
tested functionally and immune rejection issues will still prevail. Given the lack of 
curative treatments for dry eye disease, regenerative medicine has emerged as a 
promising approach to provide more permanent and sustainable therapy. To this end, our 
understanding of developmental biology, stem cell biology, and the regenerative capacity 
of the lacrimal gland is important for advancing this field of medicine. Currently, two 
main strategies are being developed for lacrimal gland repair and regeneration: i) 
capitalizing on the intrinsic regenerative capacity of the lacrimal gland,  ii) developing 
bioengineered lacrimal gland for tissue replacement.  
 
Development of fully functional bioengineered gland using in vitro cell manipulation 
technique using collagen as scaffold, can serve as a viable alternative to repair damaged 
lacrimal glands [178], however, embryonic lacrimal gland cells will be difficult to 
procure for clinical use. With the wealth of knowledge about advantages and limitations 
of using rodent and porcine lacrimal gland cells, their ability to grow on various 
biological or non-biological scaffolds in 2D or 3D formats, porcine decellularized matrix 
seeded with human lacrimal gland cells seems to be a clinically feasible option for 
developing bioengineered implants at this point. These matrices would provide the 
support structure needed for vascular, nerve and ductal supply which makes it ideal 
substitute for tissue replacement. These lacrimal gland cells need to be derived from 
human IPS cells or ex-vivo expanded autologous lacrimal gland stem cells if possible. In 
this setting, proliferation of lacrimal gland progenitor cells and differentiation to various 
cell types will be an important phenomenon aiding the development of these tissue-
derived bioengineered gland. Although these findings are highly promising, there are still 
concerns regarding the functional sustenance, cannulation, innervation and 
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vascularization of bioengineered organs, which need to be resolved and validated before 
this therapeutic approach can be applicable for clinical use [179].  
 
On the other hand, the lacrimal gland has also been shown to exhibit robust regeneration 
program as a part of wound healing process, raising the possibility that it may be feasible 
to design therapeutic strategies that take advantage of this feature. Important issues to 
consider in this context include the molecular cues that trigger regeneration, the involved 
signaling pathways, the nature and origin of the stem or progenitor cells, and whether 
these cells can be isolated and expanded in culture.  Stimulation of the intrinsic 
regenerative potential of lacrimal gland via drug or direct stem cell transplantation would 
be far less invasive and technically less challenging [180]. The emerging consensus is 
that adult lacrimal gland indeed harbors endogenous stem or progenitor cells, but their 
identity and location remains controversial. Because the existing studies are limited to in 
vitro cultures and putative stem cell markers, they may not accurately characterize 
lacrimal gland stem cells in vivo. We suggest that studies of lacrimal gland regeneration 
would benefit from the genetic approaches that have propelled the studies of lacrimal 
gland development. We have previously used the Le-Cre driver to trace the lineage of the 
Pax6-expressing cells during lacrimal gland development, showing that they strictly 
reside in the lacrimal gland epithelium, at least in new born mice [29]. With the 
increasing repertoire of inducible Cre lines, similar lineage tracing techniques should be 
readily applicable in resolving the location and nature of the lacrimal gland stem cells.  
 
With both approaches being in nascent stages, deeper understanding of lacrimal gland 
development and its regenerative potential will be required. From the development 
perspective, we still have several unanswered questions: 1) how does the common 
epithelial progenitor cell gives rise to the acinar, ductal and myoepithelial cells, 2) 
whether neural crest cell lineage is still maintained or other cell population potentially 
epithelium stem cells contribute to mesenchyme at later stages 3) whether mesenchyme 
plays any role during adult lacrimal gland maintenance, 4) what factors are required for 
adult lacrimal gland homeostasis? Future studies are needed to reveal the signaling 
cascades that underlie lacrimal gland morphogenesis and the transcription network that 
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determine the tissue identity and cell lineage for repair and regeneration. These research 
will pave the ground for achieving the full potential of regenerative medicine for the dry 
eye disease. 
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